CURRICULUM VITAE PATRICK J. SINKO, Ph.D., RPh, …sinkolab/CVFeb07.pdf · CURRICULUM VITAE PATRICK J. SINKO, Ph.D., ... Martin’s Physical Pharmacy and Pharmaceutical ... Martin’s

CURRICULUM VITAE

PATRICK J. SINKO, Ph.D., RPh, FAAPS

Office Ernest Mario School of Pharmacy Phone: 732.445.3831 x217 Rutgers, The State University of New Jersey Fax: 732.445.4271/3134 160 Frelinghuysen Road Laboratory: 732.445.3831 x225 Piscataway, New Jersey 08854-8020 EMail: [email protected] EDUCATION Bachelor of Science (Pharmacy), College of Pharmacy, Rutgers University, New Brunswick, New Jersey, 1982. Doctor of Philosophy (Pharmaceutics), College of Pharmacy, The University of Michigan, Ann Arbor, Michigan, 1988. APPOINTMENTS & EXPERIENCE Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, Parke-Davis Professor in Pharmaceutics and Drug Delivery, 2003 - 2008. Professor of Pharmaceutics, 2000 - present. Chair, Department of Pharmaceutics, 1998 - present. Associate Professor of Pharmaceutics, 1997 - 2000. Assistant Professor of Pharmaceutics, 1991 - 1997. Section Editor (Pharmaceutics and Drug Delivery), European Journal of Pharmaceutical Sciences, 2004 - present. Editor and Principal Author, Martin’s Physical Pharmacy and Pharmaceutical Sciences, Fifth Edition (appointed 2003), published November 2005. Chief Scientist, Trega Biosciences, Inc., San Diego, CA, 2000 - 2001. Co-Founder, TheraPort Biosciences, Piscataway, New Jersey, 1998. Visiting Professor, Department of Pharmacobiodynamics, Faculty of Pharmacy, Kanazawa University, Kanazawa, Japan, 1997 - 1998. Co-Founder, NaviCyte, Inc., San Diego, CA, 1996 (Chief Scientist, 1996-1999). Research Scientist, College of Pharmacy, The University of Michigan and Therapeutic Systems Research Laboratories, Inc, Ann Arbor, Michigan, 1988 - 1991. Graduate Programs Member, Graduate Program in Pharmaceutical Science, 1992 - present. Member, Joint Graduate Program in Toxicology, 1998 - present. Member, Graduate Program in Biomedical Engineering, 2003 - present.

Centers/Institutes Member (Founding), Center for Membrane Technologies, Newark, New Jersey, 1998 Member, Environmental and Occupational Health Sciences Institute, Piscataway, NJ, 1998 - present. Member, Cancer Institute of New Jersey, New Brunswick, New Jersey, 1998 - present. Member, Center for Biomaterials, Piscataway, New Jersey, 1992 - present. AWARDS AND HONORS MERIT1 Award (2006), National Institutes of Health, for grant: Enhancing Intestinal & Brain Uptake of Anti-AIDS Drugs (R37 AI/DK-51214) (see footnote below for explanation). Parke-Davis Chair in Pharmaceutics and Drug Delivery, School of Pharmacy, Rutgers University, 2003. Fellow, American Association of Pharmaceutical Scientists, (Alexandria, VA), elected in 2003. Gallo Award for Outstanding Cancer Research (with Drs. F.R. Luo, E. Rubin and A.K. Lalloo, and P.V. Paranjpe), 1999. Gallo Award for Outstanding Cancer Research (with Drs. E. Gupta, T. Cook, and E. Rubin), 1997. Hoechst Celanese Innovative Research Award ($20,000), 1995. Outstanding Teacher of the Year, Rutgers College Parents Association, Rutgers University, 1994. American Association of Pharmaceutical Scientists (AAPS) Young Investigator Grant in Pharmaceutics and the Pharmaceutical Technologies, 1993. Eli Lilly Young Investigator Award in Pharmaceutics, 1992. Burroughs Welcome Fund New Investigator Award, American Association of Colleges of Pharmacy, 1992. RECOGNITIONS 2006 “Highly accessed” refereed journal article. This article has been permanently given

“highly accessed” status. Li Wan, Simi Gunaseelan, Shahriar Pooyan, Olivia Debrah, Xiaoping Zhang, Michael J. Leibowitz, Arnold B. Rabson, Stanley Stein and Patrick J. Sinko, “Novel Multi-component nanopharmaceuticals derived from poly(ethylene) glycol bioconjugates, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects”, AIDS Research and Therapy, doi:10.1186/1742-6405-3-12, 3:12, 2006.

1. MERIT (Method to Extend Research in Time) awards from the National Institutes of Health are “awarded to a select number of investigators (<5%) who have demonstrated superior competence, outstanding productivity during their previous research endeavors and are leaders in their field with paradigm-shifting ideas. MERIT awards are intended to provide such investigators with long-term (up to 10 years), stable support to foster their continued creativity and spare them from the burden of frequent application for research grants.”

Patrick J. Sinko, page 3 2006 Selected as one of 22 founding members of the Pharmacokinetics and Drug Delivery section

of the Faculty of 1000 Biology, an international group of leading researchers in the life sciences that assesses the scientific merit of research publications.

AWARDS AND HONORS (RESEARCH GROUP)

Mr. Hilliard Kutcher, selected as a recipient of the 2006 AFPE Predoctoral Fellowship. Mr. Daniel Hertz, selected as a recipient of the 2006 NJ Center for Biomaterials Summer Fellowship. Mr. Hilliard Kutcher, selected as a recipient of the 2005 AFPE Predoctoral Fellowship. Mr. Daniel Hertz, selected as a recipient of the 2005 AFPE Gateway Fellowship. Mr. Li Wan, selected as a recipient of the 2004 NJ Center for Biomaterials Summer Fellowship. Mr. Pankaj Paranjpe, selected as the recipient of the 2003 GRASP Outstanding Poster Award. Mr. Pankaj Paranjpe, selected as a recipient of the 2003 AAiPS Research Award. Ms. Anita Lalloo, selected as a recipient of the 2003 AAiPS Research Award. Ms. Seong-Hee Park, selected as the recipient of the 2001 GRASP Outstanding Poster Award. Mr. Praveen Balimane, selected as the 1999 AAPS, Pharmaceutics, Pharmacodynamics and Clinical Sciences Award. Mr. Srinivasan Ramanathan, selected as the recipient of the 1998-1999 New Jersey Center for Biomaterials and Medical Devices summer fellowship. Mr. Navneet Puri, selected as the Best Research (Poster) Presentation, 1998 Eastern Regional Meeting of the AAPS in 1998 for his poster, Enhancement of the Adjuvancy of Muramyl Dipeptide by Controlling its Release from Ovalbumin Microspheres. Mr. Daniel A. Norris, selected as the 1997 CRS-Dow Corning Graduate Student Outstanding Research Award winner for his paper The role of surface hydrophobicity in the transport of polystyrene microspheres through Caco-2 cell monolayers and intestinal mucin. Mr. Praveen Balimane, selected as "Best Research (Poster) Presentation", 1996 Eastern Regional Meeting of the AAPS, June 1996 for his poster ACarrier-Mediated Intestinal Absorption of FLT. Mr. Daniel Norris, selected for the Award for Outstanding Podium Presentation, Controlled Drug Delivery Release Center, 1996. Mr. Daniel A. Norris, selected as Best Podium Presentation, 1996 AAPS Student Chapter Research and Information Exchange Meeting, October 1996 for his podium, Effect of Size, Surface Charge, and Hydrophobicity on the Translocation of Polystyrene Microspheres Through Gastrointestinal Mucin.

Ms. Nisha R. Patel, selected as "Best Research (Poster) Presentation", 1993 Eastern Regional Meeting of the AAPS, June 1993 for her poster "Site-Specific Oral Absorption of Anti-AIDS Drugs: Preliminary Results with Didanosine".

Patrick J. Sinko, page 4 ORGANIZATIONS & HONOR SOCIETIES

American Association for the Advancement of Science American Association of Pharmaceutical Scientists American Association of Colleges of Pharmacy American College of Clinical Pharmacy American Diabetes Association American Numismatic Association American Society of Microbiology American Society for Pharmacology and Experimental Therapeutics Controlled Release Society. The International Society for the Study of Xenobiotics The Cap and Skull Honor Society of Rutgers College, Society for leadership and character. Phi Lambda Sigma (Pharmacy Leadership Society), charter member, Lambda Chapter. Rho Chi Honor Society National Eagle Scout Association Order of the Arrow, National Scouting Honor Society.

SERVICE To the Community. Presenter "The Evolution of Pharmacy: From Magical Potions to Advanced Drug Delivery

Systems" in: The Search for Truth: Science and Myth a convocation of The Shore Consortium for the Gifted and Talented, Monmouth County, NJ, January 1994.

Presenter “Alcohol Awareness”, Boy Scout Troop 288, Annandale, New Jersey, Jan 2003. Advisor Internet Science and Technology Fair (ITSF) Team #: 02-474, Project Title “AIDS

B'GONE”, Academy for Medical Science and Technology (Middle School), Hackensack, NJ (2002-2003).

Assistant Scoutmaster, National Boy Scout Jamboree Troop 2045, Central New Jersey Council, Fort A.P. Hill, Virginia (2005).

Assistant Scoutmaster, Webmaster, and Eagle Scout Counselor, Boy Scout Troop 288, Annandale, NJ (2004-present).

To the Profession. 1992 Chairperson, Rutgers College of Pharmacy Centennial Pharmaceutics Conference. 1995 Reviewer, Scientific Proposal Review, Objective Review Committee, Food and Drug

Administration, Department of Health and Human Services, Rockville, MD. 1997 Reviewer, New Investigators Program Proposal Review, American Association of

Colleges of Pharmacy, Alexandria, VA. 1999 Reviewer, Research Proposal Review, Israel Science Foundation, Jerusalem, Israel. 2001 Reviewer, Grant Proposal, The State of Maryland Technology-Development-

Corporation, Baltimore, MD. 2003 Reviewer, Kentucky Science and Engineering Foundation R & D Excellence

Proposals, Kentucky Science and Technology Corporation, Lexington, Kentucky. 2004, 2005 External Referee, American Association of Indian Pharmaceutical Scientists Research

Awards Committee. 2005 Reviewer, Ohio Cancer Research Associates, Columbus Ohio. 2005 - Member, Pharmaceutics Advisory Committee, Pharmaceutical Research and

Manufactures of America (PhRMA) Foundation, Washington DC.

Patrick J. Sinko, page 5 Ad hoc reviewer for journals (38): AAPS PharmSci, American Journal of Physiology-Endocrinology and Metabolism, American Journal of Respiratory and Critical Care Medicine, Antimicrobial Agents and Chemotherapy, Archives of Medical Research, Biochemical Pharmacology, Biochimica et Biophysica Acta, Biopharmaceutics and Drug Disposition, Biosilico, Cancer Chemotherapy and Pharmacology, Catalysis Communications, Cellular and Molecular Life Sciences, Chemical Reviews, Clinical Cancer Research, Clinical Pharmacokinetics, Clinical Therapeutics, Drug Development and Industrial Pharmacy, European Journal of Pharmaceutical Sciences, European Journal of Pharmaceutics and Biopharmaceutics, Expert Opinion on Drug Safety, International Journal of Pharmaceutics, International Journal of Radiation Biology, Investigative Ophthalmology and Visual Sciences, Journal of Biotechnology, Journal of Controlled Release, Journal of Drug Targeting, Journal of Medicinal Chemistry, Journal of Molecular Catalysis A: Chemical, Journal of Pharmacy and Pharmacology, Journal of Pharmaceutical Sciences, Journal of Pharmacology and Experimental Therapeutics, Life Sciences Journal, Molecular Pharmaceutics, Nutrition, Pharmaceutical Research, Pharmacological Research, PreClinica, Trends in Pharmacological Sciences. National Institutes of Health (Department of Health and Human Services, Bethesda, MD.) 1992 Member (Ad Hoc), Special Study Section -7, Drug Development and Drug Delivery,

SBIR (Small Business Innovation Research) Study Section. 1998 Member (Ad Hoc), National Center for Research Resources Special Study Section,

(SBIR), Drug Development and Drug Delivery. 2001, 2002 Member (Ad Hoc), Special Emphasis Panel Study Section ZRG1 (PHRA) (1),

Bioengineering Research Partnership Review. 2001 Chair and member (Ad Hoc), NIAAA Special Emphasis Panel Study Section ZAA1

(CC05). 3/02, 6/02 Member, (Ad Hoc) Pharmacology Study Section, Center for Scientific Review. 6/03 Member, (Ad Hoc) NCI Special Emphasis Panel Study Section ZCA1 SRRB-E(02),

Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults, Bethesda, MD.

10/02 -12/03 Member, Pharmacology Study Section, Center for Scientific Review. 01/04 -06/06 Member, Xenobiotic and Nutrient Disposition and Action (XNDA) Study Section,

Center for Scientific Review. 02/04 Member, (Ad Hoc) Gastrointestinal Mucosal Pathobiology (GMPB) Study Section.11/04, 03/05 Member, (Ad Hoc) SBIR/STTR Study Section ZRG1 ONC-P (10), Cancer Drug

Development and Therapeutics. American Association of Pharmaceutical Scientists

Member, 2006 AAPS Outstanding Manuscript Award Committee. Chair, Oral Absorption Focus Group, 2006-07. Secretary-Treasurer, Section on Pharmaceutics and Drug Delivery (PDD), elected, 1995-98. Member, PDD Paper Screening Committee, 1989-90,1993-95. Member, PDD Membership Committee, 1991-1994. Chair, PDD Section Publications Committee, 1991-1995. Editor, PDD Newsletter, 1993-1995. Member, AAPS Continuing Education for Pharmaceutical Scientists Committee, 1993-1995. Member, Meritorious Manuscript Committee, 1997.

Controlled Release Society

Patrick J. Sinko, page 6

Member, Program Committee, Reviewer 1996-97. Member, Best Papers Award Committee 2001. Member, CRS Pharma Outstanding Paper Award Subcommittee, 2003-2004. Member, Awards Abstracts Review Committee, 2004 – present.

The New Jersey Center for Biomaterials and Medical Devices. Member, Industrial Relations Committee, 1993-1995.

Cancer Institute of New Jersey UMDNJ

Member, Pharmacokinetics/Pharmacodynamics Shared Resource Advisory Committee, 2004 – present.

To Rutgers University Current

Co-Chair, Organization and Administration Self-study focus group, Accreditation Self Study Committee, EM School of Pharmacy, 2006-2007. Member, Accreditation Self Study Committee, EM School of Pharmacy, 2006-2007. Faculty Advisor, Phi Lambda Sigma, EM School of Pharmacy, 2005 - . Member, Animal Care and Facilities Committee, Rutgers University, 1994 - 1998, 2005 - present. Member, Budget & Policy Committee, EM School of Pharmacy, 1997- present. Member, Space and Physical Resources Committee, EM School of Pharmacy, 2004 - present. Member, Graduate Committee, Pharmaceutical Sciences Graduate Program, 2001- present. Member, Rules of Procedure Committee, 2002-2004, 2006-2007.

Previous Due to the length of service, previous service is listed at the end of this document. EDITORSHIPS AND EDITORIAL ADVISORY BOARDS

Theme Editor, Advanced Drug Delivery Reviews, Delivery of Anti-HIV Drugs Vol. 39 Nos. 1-3 (1999). Editor and Principal Author, Martin’s Physical Pharmacy and Pharmaceutical Sciences (Fifth Edition), Lipincott Williams and Wilkins, ISBN: 0-7817-5027-X, 2003 - present. Member, Editorial Advisory Board, Molecular Pharmaceutics, 2003 - present. Section Editor on Pharmaceutics and Drug Delivery, European Journal of Pharmaceutical Sciences, 2004 - present. Member, Editorial Advisory Board, Therapy, 2004 - present. Member, Editorial Advisory Board, Advanced Drug Delivery Reviews, 2005 - present. Co-Editor, Theme Issue Drug Transporters: Integration in Understanding ADME, European Journal of Pharmaceutical Sciences, 27:5, 2006.


Member, Editorial Advisory Board, Recent Patents in Drug Delivery and Formulation, 2006 - present. Member, Editorial Advisory Board, Biomedical Materials, 2006 - present.

PROFESSIONAL LICENSES • Registered Pharmacist, Michigan, 1984. • Registered Pharmacist, New Jersey, 1982.

OTHER ACCOMPLISHMENTS Short Course Faculty, "Strategies For Oral Drug Delivery"

• September 1989: College of Pharmacy, University of Michigan, Ann Arbor, MI. • May 1991: Food and Drug Administration, Rockville, MD.

Short Course Faculty, “AFDA Field Investigators Short Course in Pharmaceutical Science” June 1995, Rutgers University. Short Course Coordinator and Faculty, “Absorption Pharmacokinetics: Mechanisms, Intestinal Permeability, and Mass Balance Correlations”, September 1996, Food and Drug Administration, Rockville, MD. Short Course Faculty, “Drug Transporters: Physiology, Design and Application I and II” February 2005, CDER, Food and Drug Administration, Rockville, MD.

TEACHING Undergraduate/Professional Degree.

1. Introduction to Pharmaceutics (30:721:301): Lecturer, 1992-97, 2002-; Course Coordinator, 1992 - 94.

2. Introduction to Pharmacokinetics (30:721:302): Lecturer, 92 – 01; Course Coordinator, 1996 - 2001.

3. Drug Delivery I (30:721: 320): Lecturer, 2005 – present. 4. Drug Delivery II (30:721:420): Course Coordinator and Lecturer, 1999; Lecturer, 2002 –

present. 5. Introduction to Pharmacology ( 30:718:320), 2001- present. 6. General Toxicology (16:963:501), 2003 – present. 7. Problems in Pharmaceutics (16:721:496/8), Advisor for: 1992-1993: B. Naik, V. Phillips and

S. Phan; 1993-1994: M. Milecofsky, D. Sanderson, K. Pandya and S. Phan (Fall); D. Assef, C. Frost, M. Heyman, R. Kalia, S. Ma, M. Milecofsky, M. Wainright (Spring); 1994-1995: J. Jeges (Fall), L. Barbarello (Spring); 1995-1996: J. Ellen (Fall); 1996-1997: C. Aumack, J. Kuti, N. Shah, K. Yang (Fall); 1997-1998: S. Singh, S. Puri, N. Asadollahi, P. Meswani; 1998-1999: N. Shah; 1999-2000: W. Marinaro and J. Thomas (Fall), W. Marinaro, D. Alvarez, A. Capuno, J.Y. Oh and J. Thomas. (Spring); 2000-2001: Sejal Bhagat.

Honors Programs.

Ms. Karen Ludwig, College of Pharmacy, Class of 1996 (Primary Advisor). Ms. Mayuko Imai-Shapiro, Mable Smith Douglass Honors Program, (Second Reader).


Mr. Andrew Iskander, Henry Rutgers Scholars Program, 1997-1998 (Primary Advisor) Ms. Melissa Pao, College of Pharmacy 1999-2003 (Primary Advisor). Mr. Mikhail Domantivsky, College of Pharmacy 2000-2003 (Primary Advisor). Mr. Daniel Hertz, School of Pharmacy, 2004 - (Primary Advisor). Ms. Somi Kim, School of Pharmacy, 2006 – (Primary Advisor).

Doctor of Pharmacy Program.

Advanced Clinical Pharmacokinetics (31:725:509), Lecturer, 1994 - 1998.

Graduate Program in Pharmaceutical Sciences. 1. Lecturer (50%), Advanced Pharmaceutics II(16:720:509), 2001- 2005. 2. Coordinator and Lecturer, Advanced Pharmaceutics I (16:720:507), 2000- present. 3. Lecturer, Cellular and Molecular Pharmaceutics (16:720:608), 2000, 2002. 4. Lecturer, Advances in Drug Metabolism and Disposition (16:720:608). 5. Lecturer, Therapeutic Peptides and Delivery Systems, (16:720:520). 6. Coordinator, Graduate Seminar in Pharmaceutical Sciences (16:720:601/2), 1994-1995,

1998-1999, 2006. 7. Lecturer, Special Topics: Advanced Biopharmaceutics and Pharmacokinetics (16:720:608),

1997. 8. Lecturer, Biochemical Toxicology(16:963:505), 2002 - present. 9. Coordinator and Lecturer, Nanotechnology-Based Drug Delivery(16:720:550), 2006 –

present.

Graduate Program in Psychology Advanced Studies in Psychology (16:830:503:01).

Graduate Program in Biomaterials Engineering

Biomaterials Applications: Drug Delivery Systems (BME:125:622) 1999. Graduate Program in Physiology

Mammalian Physiology: Pharmacokinetics of Insulin, a metabolic hormone (16:761:502), 1999 - 2002.

Project SEED, American Chemical Society. Anil Dookie, Summer 1994. RU MAPPS, Rutgers University Minority Apprenticeship Pre-College Program in Science, Sandra Fernandez, 1996. Douglass Project for Rutgers Women in Math, Science and Engineering Mentor Project, Elena Ginorio, 2000

Patrick J. Sinko, page 9 GRADUATE STUDENTS Name Degree/Date

Thesis Title Company Current Position

Nisha R. Patel M.S. 1994

Characterization of the Oral Absorption of AIDS Anti-Infectives: Investigating the Mechanism and Site-Dependent Absorption of Didanosine

Anthony P. Waclawski Ph.D. 1996

Oral Absorption of Anti-HIV Nucleoside Analogues: The Mechanism of Intestinal Absorption and Metabolism of Stavudine

Bristol-Myers Squibb Director

Jennifer P. Niznik M.S. 1997

The Utility of Biodegradable Polymers in Oral Vaccine Delivery

Daniel A. Norris Ph.D 1998

The Effect of Surface Hydrophobicity on Microparticle (MP)-Mucin and MP-Caco-2 Cell Interactions

Anadys Pharmaceuticals, Inc. Senior Scientist

Navneet Puri Ph.D. 1999

Adjuvancy Enhancement of Muramyl1 Dipeptide (MDP) by Modulating its Release from a Physicochemically Modified Matrix of Ovalbumin Microspheres

InnoPharma, Inc. President

Praveen V. Balimane Ph.D. 1999

Characterization of the Interactions of a Non-Peptide Drug (Valacyclovir) with the Intestinal Peptide Transporter, hPepT1

Bristol-Myers Squibb Senior Research Investigator

Anita Lalloo M.S. 1999

Investigation of the Intestinal Transport Mechanisms of the Camptothecins Using Cell Culture Models

Merck & Co., Inc. Senior Scientist

Srinivasan Ramanathan Ph.D. 2001

Targeting the Biotin Transporter to Enhance the Intestinal Transport of a Retro-Inverso TAT Nonapeptide and its Polymeric Conjugate

Gilead Sciences, Inc. Research Scientist

Jeevan Kunta Ph.D. 2002

Investigation of the role of intestinal extraction on oral bioavailability

GlaxoSmithKline Research Scientist

Gregory C. Williams Ph.D. 2002

The Roles of Multiple Transporters in the Intestinal Absorption of Saquinavir, A Peptidomimetic HIV Protease Inhibitor

NPS Pharmaceuticals Vice President Corp Planning

Anita Lalloo Ph.D. 2004

Controlled Release of the Camptothecins from a Novel In Situ forming Hydrogel

Merck & Co., Inc. Senior Scientist

Pankaj Paranjpe Ph.D. 2004

Tumor-Targeted and Activated Bioconjugates for Improved Camptothecin Delivery

Bristol-Myers Squibb Research Scientist

Seonghee Park Ph.D. 2005

Investigation of the Role of Transporters in the Absorption and Secretion of Drugs Across the Blood-Brain Barrier

Wyeth Post Doctoral Research Scientist

Piyun Chao Ph.D. 2006

Parenterally-administered, passively targeted pulmonary drug delivery system with enhanced retention properties

Hurel Inc. Research Scientist

Helen Usansky Ph.D. 2005

Assessing the Influence of PGP, MRP2 and CYP3A Modulation on Oral Drug Absorption

Johnson and Johnson Principal Scientist, PKPD

Yaming Su Ph.D. 2006

The Role of Efflux Transporters in the Pharmacokinetics and Pharmacodynamics of

GlaxoSmithKline Principal Scientist

Patrick J. Sinko, page 10 Anti-cancer Drugs Li Wan Passed written preliminary exam (02/05)

Wyeth Research Scientist

Sung-Hack Lee Passed written Preliminary exam (09/05) Hill Kutscher Helen Cui Ethicon Swathi Pinnamaneni Bristol-Myers Squibb Sree Priya Anumolu Peiming Chen Matthew Palombo Sherif Ibrahim

Thesis Committees. The University of Michigan, Ann Arbor, MI. Doo-Man Oh, Ph.D. “Estimating Oral Drug Absorption in Humans”, 1991.

Rutgers University, Piscataway, NJ. 1. HongKee Sah, Ph.D. “The Controlled Release of Protein from Biodegradable Multireservoir

Microcapsules”, 1994. 2. Mona Nair, Ph.D. “Characterization of Buccal Mucosa and Development of a Mucoadhesive Dosage

Form for Drug Delivery in the Oral Cavity”, 1994. 3. Robert Orr, Ph.D. “Interactions of Water Vapor with Pharmaceutical Elastomeric Closures”, 1995. 4. Haresh Mirchandani, Ph.D. “Intestinal Absorption of Anti-HIV Drugs: Development of a Multi-

Loop In Situ Technique, “Characterization and Mechanistic Analysis”, 1995. 5. Dae-Duk Kim, Ph.D. “Transdermal Delivery of Anti-HIV Drugs”, 1995. 6. Chi Lee, Ph.D. “Intravaginal Controlled Delivery of Spermicidal Agents: Characterization of

Spermicidal Activity and Development of a Mucoadhesive Delivery System”, 1995. 7. Yaling Lee, Ph.D. “Oral Mucosal Delivery of LHRH and the Development of Mucoadhesive

Polymer Systems”, 1995. 8. Chun Yu (Chemistry), Ph.D. “Development and Evaluation of New Biodegradable Materials”, 1996. 9. Deborah A. Spina, M.S. “A Novel In Vitro Method to Predict In Vivo Bioavailability of PAH

Sorbed to Soil”, 1998. 10. Matthew Hoffmann, Ph.D. “Pharmacokinetics of Benzine After an Oral or Dermal Dose in the

Tg:AC Mouse and Metabolism of Benzene in the Isolated Perfused Mouse Liver”, 2000. 11. Shahriar Pooyan, Ph.D. “Chemical Modifications for improvement of the Pharmacologic Properties

of Therapeutic Agents”, 2001. 12. Dea Herrera, Ph.D. “Investigations into the Molecular and Transport Characteristics of Established

and Putative Peptide Transporters”, 2002. 13. Shilpi Agarwala, M.S. “Effect of Pesticides on the Expression and Function of Intestinal P-

glycoprotein”, 2002. 14. Sonia Dharap, Ph.D. “Molecular Targeting of Drug Delivery Systems to Ovarian Cancer By BH3

and LHRH”, 2005. 15. Yan Xu, Ph.D. “Effects of di- (ethylhexyl)-phthalate (DEHP) and selective metabolites on placental

fatty acid homeostasis”, 2006. 16. Seema Betigeri, PhD, in progress. 17. Brian Yeagy, Ph.D., in progress.

Patrick J. Sinko, page 11 POSTDOCTORAL AND RESEARCH ASSOCIATES AND VISITING SCIENTISTS Name Degree Dates of stay Peidi Hu M.S. 1992 - Fuxing Jiang M.S. 1992 - 1993 Vinay Sharma Ph.D. 1993 - 1996 Hongshi Yu Ph.D. 1994 - 1997 Barbara Perry M.S. 1994 - 2003 Thomas Cook Ph.D. 1995 - 1997 Vijaya Makhey Ph.D. 1995 - 1998 Zahra Mahmoudi Ph.D. 1995 - 1996 Jiansheng Yan M.S. 1996 - 1998 Ronald Benjamin B.S. 1996 - 1997 Rongdi Shan B.S. 1996 - 1997 Stacy LaBruno B.S. 1997 - 2003 Ailan Guo Ph.D. 1997 - 2001 Yong Hee Lee Ph.D. 1998 - 1999 Heesang Lee M.D. 1998 - 2001 Roger Feng Luo Ph.D. 1998 - 2000 Xaioping Zhang Ph.D. 1999 - Katherine Meyer B.S. 2000 - 2002 Lingni Huang B.S. 2000 Ignacio Segarro Ph.D. 2000 - 2002 Bo Qiu Ph.D. 2000 - 2002 Raina M. Rigoli B.S. 2001 - 2002 Guobao Zhang Ph.D. 2001 - 2002 Olivia Debrah B.S. 2002- Shariar Pooyan Ph.D. 2002, 2005 - Ramesh Chintila Ph.D. 2002 Simi Gunaseelan Ph.D. 2002- Temidayo Adegboye Ph.D. 2003-2004 Li-Heng Pao Ph.D. 2005 Yashveer Singh Ph.D. 2005 - Manjeet Deshmukh Ph.D. 2005 - Dayuan Gao Ph.D. 2005 - Nitin Gandhi Ph.D. 2005 - 2006. Raghavendra Navath Ph.D. 2006- SCIENTIFIC ADVISORY BOARDS Member, Metacrine Sciences 1998 Chair, TheraPort Biosciences 2002 Member, Spherics, Inc. 2006 – present ADVISORY PANELS Wyeth Ayerst 1993, 1994 Lederle Laboratories 1994

Patrick J. Sinko, page 12 Novo Nordisk (US) 1996 Alza Corporation 2000 - 2004 Abbott 2001 CONSULTANCIES Alza Corporation 1993, 2000 - 2005 Wyeth Ayerst 1993 - 1996 Sandoz Pharmaceuticals Corp. 1994 - 1995 Geneva 1995 - 1996 Ribi ImmunoChem Research, Inc. 1996 - 1997 Biogen Corporation 1996 -1997 Novo Nordisk A/S (Denmark) 1996 - 1997 Uniroyal Chemical Company, Inc. 1996 - 1997 Warner-Lambert Company 1997 Glaxo-Wellcome PLC 1997 - 1998 Teva Pharmaceuticals, USA 1998 Wyeth Ayerst 1998 Trega Biosciences, Inc. 1999 - 2001 Merck & Co. 1999 Eli Lilly & Co. 2000 Nobex Corp. 2000 - 2005 Affymax 2000 Spherics, Inc. 2000 – 2004 Lion Bioscience, Inc. 2000 - 2002 Abbott Laboratories 2001 Syntonix 2002 – 2004 Genteric 2003 – 2004 Pfizer, Inc. 2005 Expert Testimony (Patent Litigations)

1. Hoecsht Marion Roussel v. Geneva Pharmaceuticals. 2. SmithKline Beecham v. Ranbaxy Laboratories, No. 3:03-cv-02158-MLC-JJH, (D.N.J. filed

May 9, 2003). 3. Biovail Laboratories v. Abrika, LLLP, No. 0:04-cv-61704, (S.D.Fl., filed December 21,

2004). RESEARCH INTERESTS

Synopsis: Drug delivery and targeting with an emphasis on AIDS and cancer, biomaterials, hydrogels and nanocarriers, mechanism-based pharmacokinetics and biopharmaceutics; transport and metabolism, and bioavailability.

RESEARCH SUPPORT ($12,786,259 total as Principal Investigator)

Current 1. UMDNJ/Rutgers University CounterACT Research Center of Excellence; 9/28/06-9/28/11,

PHS, NIH, Total Costs $18,686,008, Principal Investigator: J.D. Laskin; Patrick J. Sinko (Director, Medicinal Chemistry and Pharmaceutics Scientific Core), $250,000 (Sinko Portion annual direct costs), $379,600 (Sinko Portion annual total costs).


2. Enhancing Intestinal & Brain Uptake of Anti-AIDS Drugs; 04/01/02 – 2/28/11 (current

renewal period: 3/01/06-2/28/11), National Institution of Allergy and Infectious Diseases (R37* AI/DK-51214) PHS, NIH, Total Costs (Renewal) $1,730,072, Total Costs $2,815,072, Principal Investigator: P.J. Sinko. *awarded MERIT status in May 2006.

3. Advanced Drug Delivery Systems; 01/15/05 – 05/14/08, Westward Pharmaceuticals

Corporation (Hikma Pharma PLC), Total Costs $1,972,665, Principal Investigator: P.J. Sinko.

4. EPR Assembly of Microgel for Fret Imaging of Breast Cancer; 02/15/05 - 2/14/08, US Army Medical Research and Material Command (USARMRMC) Total Costs $ 465,567, Co-Investigator: P.J. Sinko.

5. Transdermal Drug Delivery Using Iontophoresis in Yorkshire Swine, 03/01/03 – 05/31/07,

Vyteris Inc., $326,343, Principal Investigator: P. J. Sinko. Completed 6. Evaluation of HydronTM Subcutaneous Implants in Dogs, 04/01/03-12/31/06, Valera

Pharmaceuticals, $260,694, Principal Investigator: P.J. Sinko. 7. Enhancing Intestinal & Brain Uptake of Anti-AIDS Drugs; 4/01/02-2/28/06, National

Institution of Allergy and Infectious Diseases (R01 AI/DK-51214) PHS, NIH, Total Costs $1,085,000, Principal Investigator: P.J. Sinko.

8. Oral Bioavailability and Variability of Anti-AIDS Drugs; 04/01/98 - 03/31/01, National Institution of Allergy and Infectious Diseases (R01 AI42007) PHS, NIH, $386,657, Principal Investigator: P.J. Sinko.

9. Oral absorption and biopharmaceutics of anti-HIV drugs, 12/92-12/97, $521,870, PHS, NIH, National Institute of Allergy and Infectious Diseases (AI33789), Principal Investigator: P.J. Sinko.

10. In Vitro Device for Cell Culture-based Screening, 7/97 - 12/97, $100,000, PHS, NIH, National Institute of General Medical Sciences (GM56594), Coinvestigator.

11. Oral Bioavailability and Variability of Anti-AIDS Drugs; 09/30/97 - 9/29/98, National Institution of Allergy and Infectious Diseases (R21 AI42007) PHS, NIH, $134,422, Principal Investigator: P.J. Sinko.

12. Oral Peptide Delivery, 04/01/02 - 12/31/03, Nobex Corporation, $158,145, Principal Investigator: P.J. Sinko.

13. Antiviral Efficacy in a Mouse Model, 10/01/01-2/28/03, Luminide Pharmaceutical Corporation, $11,071, Principal Investigator: P.J. Sinko.

14. Biopharmaceutics of Anticancer Agents, 08/01/00 - 2/28/03, Supergen Pharmaceuticals, Inc., $336,500, Principal Investigator: P.J. Sinko.

15. Integrated approach for the development of novel formulations for the oral delivery of small proteins, 10/92-10/01, $2,106,425, Unigene Laboratories, Inc., Principal Investigator: P.J. Sinko.

16. Oral Delivery of Low Molecular Weight Heparin in Dogs, 12/05/99 - 12/14/00, Elan Corp., $353,707, Principal Invesitgator: P.J. Sinko.

17. Oral Delivery of Oligonucleotides, 04/01/99 - 12/31/00, Isis Pharmaceuticals, Inc., $218,174, Principal Investigator: P.J. Sinko.

18. Oral Absorption and Biopharmaceutics of BG-9719, an Adenosine 1 Antagonist, 8/97 - 3/00, Biogen, Inc., $401,088, Principal Investigator: P.J. Sinko.


19. Studies on the Gastrointestinal Absorption of Nonane, 04/97 - 12/97, $32,000, Exxon Biomedical Research, Coinvestigator.

20. Drug Delivery System (DDS) for MS, 10/10/03 - 03/15/2004, Elan Corporation , $27,210, Principal Investigator: P.J. Sinko.

21. Pharmacokinetic Studies in Dogs, 05/01/01-4/30/03, Nobex Corporation, $384,303, Principal Investigator: P.J. Sinko.

22. Factors Affecting Oral Bioavailibity of Camptothecins; 4/01/98 - 3/31/01, American Cancer Society (RPG_98-057-01-CCE) $328,000, Year 1:Co- Investigator, Years 2&3 Principal Investigator: P.J. Sinko.

23. Intestinal Dosing in IVAP Rabbits, 03/15/03-4/30/03, Syntonix Pharmaceuticals, $5,460, Principal Investigator: P.J. Sinko.

24. Predicting Absorption Enhancing Effects of Pharmaceutical Excipients Using the In Vitro Caco-2 Cell Culture System, 8/16/96 - 8/15/97, $63,030, Ciba-Geigy Corporation, Pharmaceuticals Division, Principal Investigator: P.J. Sinko.

25. Development of a Pulsatile, Microparticulate Captopril Oral Delivery System - Phase I, 7/96 - 1/97, $27,266 Sharmatek, Inc. (Wockhardt, Ltd.), Principal Investigator: P.J. Sinko.

26. Ileal and duodenal absorption of calcitonin in normal healthy volunteers, 8/94-6/95, $18,898, Unigene Laboratories, Coinvestigator.

27. Use of novel biomaterials and processing techniques in the development of advanced drug and vaccine delivery systems, 7/1/94 - 6/30/95, Associated Institutes of Material Science, $78,850, PI.

28. Pharmacokinetic evaluation, 10/92-10/94, $12,446, Unigene Laboratories, Inc., PI. 29. Oral Delivery Using Pulsatile Macroparticles, 1/94 - 11/95, Sharmatek, Inc., $6,600, PI. 30. Technology for improved oral delivery of anti-HIV drugs, 7/92-9/93, $15,931, TSRL, Inc., PI. 31. Investigation of the intestinal mucosal cell transport of anti-HIV nucleoside analogues, 8/92 -

6/93, $5,000, AACP, PI. 32. Intestinal mucosal metabolism and transport of drugs: Membrane vesicles, 7/92-6/93, $4,000,

BRSG special award, PI. 33. Preliminary investigation into the intestinal metabolism of anti-AIDS drugs, 7/92-6/93,

$2,000, Rutgers Research Council, PI. Other Support.

1. Research Capacity Fund, State of New Jersey/Commission on Higher Education, 03/01/01-06/30/02, $608,321, Principal Investigator: P. J. Sinko

2. Research Capacity Fund, State of New Jersey/Commission on Higher Education, 09/28/01-06/30/03, $300,000, Principal Investigator: P. J. Sinko.

Fellowships.

1. 2005-2006, 2006-2007 AFPE Predoctoral Fellowship, 9//01/05-8/31/07, $12,000, Hilliard Kutscher.

2. 2006 NJ Center for Biomaterials Summer Fellowship, $2,400, Daniel Hertz. 3. 2005 AFPE Gateway to Research Scholarship, 6/01/05-5/31/06, $5000, Daniel L. Hertz and

Patrick J. Sinko. 4. 2004 – 2006, Novartis Student Internship, 05/13/04 –9/15/06, Novartis Pharmaceuticals,

$91,250, P. J. Sinko. 5. 1999 – 2005, Post- & Pre-Doctoral Fellowships, 01/01/99-12/31/05, Bristol-Meyers Squibb,

$500,000, P. J. Sinko. 6. 2004 NJ Center for Biomaterials Summer Fellowship, 7/1/04-8/31/04, $3,000, Li Wan.


7. 2001 NJ Center for Biomaterials Summer Fellowship, 7/1/01-8/31/01, $2,500, Seong-Hee Park.

8. 1995-1997 American Foundation for Pharmaceutical Education Pre-Doctoral Fellowship, Daniel A. Norris.

9. 1994 New Jersey Center for Biomaterials and Medical Devices Summer Fellowship, Daniel A. Norris.

PATENTS Issued Patents (7) 1. P.J. Sinko with co-inventors: G.L. Amidon, G.D. Leesman, "Enhancing the Bioavailability of

Proteolytically Labile Therapeutic Agents", United States Patent 6,153,592 (issued 11/28/2000). 2. Patrick J. Sinko with co-inventors: M. Leibowitz, S. Stein, “A Carrier for In Vivo Delivery of a

Therapeutic Agent”, United States Patent 6,258,774 (issued July 10, 2001). 3. Patrick J. Sinko with co-inventors: M. Leibowitz, S. Stein, “A Carrier for In Vivo Delivery of a

Therapeutic Agent”, United States Patent 6,617,306 (issued September 9, 2003). 4. Patrick J. Sinko with co-inventors: Mike Leibowitz, Stanley Stein, “Materials and Processes For

Controlled Release of Thio-amide Moiety Containing Therapeutic Agents by Linking to Thiol-Containing Polymets”, United States Patent 6,468,522 (issued October 22, 2002).

5. Patrick J. Sinko with co-inventors: G.M. Grass, G.D. Leesman, D.A. Norris, J.E. Wehrli, “Pharmacokinetic-based drug design tool and method” United States Patent 6,542,858 (issued April 1 2003).

6. Patrick J. Sinko with co-inventors: G.M. Grass, G.D. Leesman, D.A. Norris, J.E. Wehrli, “Pharmacokinetic-based drug design tool and method” United States Patent 6,647,358 (issued November 11, 2003).

7. Patrick J. Sinko with co-inventors: G.M. Grass, G.D. Leesman, D.A. Norris, J.E. Wehrli, “Method for screening and producing compound libraries” United States Patent 6,996,473 (issued February 7, 2006).

Pending Provisional and Full Patent Applications (7) 1. Patrick J. Sinko with co-inventors: J. Athwal, C. Sage, T. Bremer, G.M. Grass, K. Holme, Y-H.

Lee, K. Lee, G.D. Leesman, D.A. Norris, “Regional Intestinal Permeability Model”, Canadian, European, and United States Patents Pending (published September 16, 2004).

2. Patrick J. Sinko with co-inventors: J. Athwal, C. Sage, T. Bremer, G.M. Grass, K. Holme, G.D. Leesman, D. Norris, “System and Method for Predicting ADME Tox Characteristics of a Compound”, United States Patents Pending (published January 15, 2004).

3. Patrick J. Sinko with co-inventors: M. Leibowitz, T. Minko, P. Paranjpe, S.H. Park, S. Pooyan, B. Qiu, S. Ramanathan, S. Stein, G.C. Williams, G. Zhang, X. Zhang, “Enhanced Oral and Transcompartmental Delivery of Therapeutic or Diagnostic Agents” United States Patent Pending, Serial number 11/170,652, Rutgers Docket number 10-089 (filed June 29 2005).

4. Patrick J. Sinko with co-inventors: M. Leibowitz, B. Qiu, S. Stein, “Multiple Phase Cross-Linked Compositions and Uses Thereof” United States Patent Pending, Serial number 09/883,842 (published June 18, 2001).

5. Patrick J. Sinko with co-inventors: S. Pooyan, S. Gunaseelan, S. Stein, L. Wan, X. Zhang, “Drug-Polymer Conjugates Coupled To A Peptidic Carrier” United States provisional patent pending, 60/653,125 (April 2006).

6. Patrick J. Sinko with co-inventors: P. Chao, P. Hu, S. Stein, “Novel Controlled Released Drug Delivery System And Enhanced Passive Targeting And Retention” United States provisional patent pending, 60/692,150, Rutgers Docket number 05-137 (filed June 2006).

Patrick J. Sinko, page 16 7. Patrick J. Sinko with co-inventors: M. Desmukh, S. Gunaseelan, Y. Singh, S. Stein, “Temporal-

controlled Biodegradable Hydrogels for Delivery of Anti-Cancer Agents”, pending.

INVITED LECTURES (116) 1. "Predicting Fraction Dose Absorbed in Humans for Peptides and Peptide-like drugs", AAPS

Midwest Regional Meeting; May 1989, Chicago, IL.

2. "Macroscopic Mass Balance Analysis Approach to Predicting Oral Drug Absorption", AAPS Annual Meeting, Pharmaceutics and Drug Delivery Symposium; October 1989, Atlanta, GA.

3. "Use of in situ / in vitro Parameters To Estimate Oral Drug Absorption in Humans: Mass

Transport and Scaling Considerations", North Eastern Regional Pharmaceutics Association, April 1990, Waterbury, CT.

4. "Carrier Mediated Intestinal Drug Transport: Experimental Characterization of Absorption and

Prediction of Extent of Absorption in Humans", Lederle Laboratories, May 1991, Pearl River, NY.

5. "Mechanisms of Intestinal Peptide Transport and Metabolism", AAPS Annual Meeting, Clinical

Sciences Symposium, November 1991, Washington, DC.

6. "Challenges and Prospects for the Oral Delivery of Peptides", Unigene Laboratories, Inc. April 1992, Fairfield, N.J.

7. "The Challenges of Developing Oral Delivery Systems for Therapeutic Macromolecules",

Emisphere Technologies, Inc. July 1992, Hawthorne, N.Y.

"The Oral Delivery of Therapeutic Peptides and Small Proteins: Mechanisms and Strategies" 8. September 1992, The R.W. Johnson Pharmaceutical Research Institute. Raritan, N.J. 9. November 1992, Parke-Davis Research, Warner-Lambert Company, Morris Plains, NJ.

10. "The Oral Delivery of Macromolecules: Myth and Reality", Hudson Valley Pharmaceutics

Discussion Group. November 1992, Saddle Brook, N.J.

"Differential Oral Absorption of Water Soluble Drugs" 11. June 1993, Emisphere Technologies, Inc., Hawthorne, New York. 12. August 1993, Burroughs-Wellcome Company, Research Triangle Park, North Carolina. 13. September 1993, Eli Lilly and Company, Indianapolis, Indiana. 14. October 1993, Sandoz Pharmaceuticals Corporation, East Hanover, New Jersey.

15. "The Challenge of Developing Oral Delivery Systems for Pharmaceutical Macromolecules",

Indianapolis-Cincinnati Pharmaceutics Discussion Group, September 1993, Indianapolis, Indiana.

16. "Material Aspects in the Oral Delivery of Pharmaceuticals", The Second New Jersey Symposium on Biomaterials and Medical Devices, November 1993, Piscataway, New Jersey.

"Mechanisms and Modulation of Regional Oral Drug Absorption" 17. January 1994, Pfizer Central Research, Groton, Connecticut.

Patrick J. Sinko, page 17 18. May 1994, Alza Corporation, Palo Alto, California. 19. May 1994, Genentech, Inc., South San Francisco, California. 20. June 1994, Pfizer Central Research, Sandwich, Kent, UK.

21. "Use of In Vitro Methods to Characterize the Intestinal Transport of Poorly Absorbed

Compounds", Experimental Biology '94J, Federation of American Societies of Experimental Biology, April 1994, Annaheim, California.

22. "Concentrative Intestinal Uptake of Stavudine (d4T) in Rats and Correlation with Bioavailability

in Humans", Second Annual Scientific Retreat, The Cancer Institute of New Jersey, June 1994.

23. "Regional Oral Bioavailability: Intestinal Transport and Metabolism of Captopril and Didanosine", College of Pharmacy, The University of Maryland, November 1994.

“Regional Oral Bioavailability of Peptides” 24. January 1995, Alza Corporation, Palo Alto, California. 25. February 1995, AAPS/ACCP Symposium on Preclinical and Clinical Pharmacology Issues with

Proteins and Peptides, San Diego, California.

26. “Comparison of In Vitro and In Situ Methods for Assessing the Intestinal Permeability of Biologically Active Molecules", Experimental Biology '95J, Federation of American Societies of Experimental Biology, April 1995, Atlanta, Georgia.

27. “Biopharmaceutical Challenges to Delivering Vaccines Orally”, Ribi ImmunoChem Research,

Inc., August 1995, Hamilton, Montana.

28. “Bioavailability Correlations in Drug Discovery and Development: Applications to Permeability Determination and Setting Controlled-Release Specifications”, Lilly Research Laboratories, Eli Lilly and Company, September 1995, Indianapolis, IN.

29. “Comparison of In Vitro and In Situ Methods for the Assessment of Intestinal Permeability”, in:

Tools for Predicting Human Oral Absorption Symposium; Tenth Annual Meeting, American Association of Pharmaceutical Scientists, November 1995, Miami Beach, FL.

“Metabolism and Permeability Models Used in Support of Drug Discovery and Product Development” 30. February 1996, Wyeth-Ayerst Research, Pearl River, New York. 31. February 1996, Schering-Plough Corporation, Kenilworth, New Jersey. 32. February 1996, Biogen Corporation, Cambridge, Massachusetts.

33. “Absorption Variability of Water Soluble Compounds”, in: Formulation Technologies at the

Cutting Edge: Highly Polar Compounds Symposium, American Association of Pharmaceutical Scientists, Eastern Regional Meeting, June 1996, New Brunswick, NJ.

34. “Biopharmaceutical Approaches for Developing Rational Oral Drug Delivery Strategies”,

Bristol-Myers Squibb, October 1996, New Brunswick, NJ.

35. “The Roles of Regional Intestinal Permeability and Metabolism in the Variability of Oral Extended-Release Product Performance”, in: In Vitro -In Vivo Correlations of Dosage Form


Performance for Design and Approval Symposium, National Meeting of the American Association of Pharmaceutical Scientists, October 1996, Seattle, WA.

36. “The Utility and Limitations of Cell Culture Methods in Investigating Drug Transport and

Metabolism” North Jersey - American Chemical Society Drug Metabolism Discussion Group, November 1996, Somerset, New Jersey.

37. “Molecular and Cellular Determinants of Oral Drug Bioavailability” Glaxo Wellcome, February

1997, Research Triangle Park, NC.

38. “Developing an In Vitro - In Vivo Correlation for Dynacirc CR. Importance of Release Rate and Dissolution Rate”, AAPS/CRS/FDA Workshop, April 1997, Arlington, VA.

39. “Anti-AIDS Drugs: The Multiplicity of Absorption Mechanisms and Impact on Bioavailability”,

Uppsala University, April 1997, Uppsala, Sweden.

40. “Macroscopic Factors Controlling Oral Drug Absorption” 1997 Congress on In Vitro Biology, June 1997, Washington, D.C.

41. “Regional Functional Expression and Kinetics of Intestinal Drug Efflux in Laboratory Animals,

Caco-2 cell Monolayers, and Humans”, Kanazawa University, Kanazawa, Japan, October 1997.

“The Importance of High-Throughput Pharmacokinetic Screening in Drug Discovery” 42. Novel Strategies for Accelerated ADME/Toxicity Screening for Lead Optimization, December

1997, Philadelphia, PA. 43. Screen 98 Assay Development for High-Throughput Screening, January 1998, San Diego, CA.

“High-Throughput Pharmacokinetic Screening: Strategies and Methods” The Role of Intestinal Efflux/Secretory Transport in Determining Oral Bioavailability 44. NIEHS Center Core I Seminar, February 1998, Piscataway, NJ. 45. Nagoya City University, March 1998, Nagoya, Japan.

46. "High-Throughput Pharmacokinetic Screening Tools and Methods for Enhancing the Drug

Selection Process” NMHCC Discover -98 Emerging Technologies for Drug Discovery, May 1998, San Diego, CA.

47. “The Importance of High Throughput Pharmacokinetic Screening in Drug Discovery.” High

Throughput In Vitro Technologies for Pharmacokinetic Assessment During Drug Discovery and Development, 1998 Meeting of the Society for In Vitro Biology, June 1998, Las Vegas, NV.

48. “Developing Strategies for Enhancing the Transport of Polypeptides: Enhancing Permeability and

Stability.” In Vitro Techniques for Investigating the Intestinal Transport of Poorly Absorbed Drugs, 1998 Meeting of the Society for In Vitro Biology, June 1998, Las Vegas, NV.

49. “High-Throughput Pharmacokinetic Screening Tools and Methods for Enhancing the Drug

Selection Process” High Throughput Screening for Drug Discovery June 1998, Dallas, TX.

“The Multiplicity of Intestinal Absorption Mechanisms and Impact on Oral Bioavailability” 50. Novartis Pharmaceuticals, June 1998, Summit, NJ.

Patrick J. Sinko, page 19 51. Cancer Institute of New Jersey, Cancer Pharmacology Program Meeting, July 1998, Piscataway,

NJ. 52. State University of New York at Buffalo, August, 1998 Buffalo, NY.

53. “Challenges and Strategies for Intranasal Drug Delivery” Wyeth-Ayerst Research, July 1998,

Princeton, NJ.

54. “Interfacing Drug Discovery and Preclinical Pharmacokinetics - Scientific Limitations and Current Bottlenecks” Targeted Bioavailability, Gordon Research Conference, August 1998, New London, NH.

55. “Intestinal Perfusion for Determining Gastrointestinal Permeability” AAPS Workshop on

Permeability Definitions and Regulatory Standards for Bioequivalence, August 1998, Arlington, VA.

56. “Evaluation of Drug Bioavailability” Exploiting the Commercial Benefits of Pharmacogenomics

& Pharmacogenetics for Drug Discovery, Development & Diagnostics, September 1998, London, UK.

57. “Computational Pharmacokinetics for Drug Discovery B Interfacing High Throughput

Pharmacokinetics (HTPkS) and Pk-Informatics” Optimizing Lead Selection and Early Attrition Improving the Survivability fo Drug Candidates in Clinical Trials , September 1999, Philadelphia, PA.

“The Roles of Transporters and Enzymes as Oral Drug Delivery Barriers and Opportunities” 58. Purdue Pharma, December 1999, Ardsley, NY. 59. DuPont Pharma, December 1999, Wilmington, DE.

60. “Preclinical Models to Predict Oral Absorption in Man”, Merck and Company, February 2000,

West Point, PA

61. “Novel Miniaturized Platforms for ADME/ Tox Assays”, IBC’s 3rd Annual International Miniaturization Technologies, March 2-3, 2000, Monterey, CA.

62. “Predicting Human Drug Absorption Properites from In Vitro Data using Physiological-and

Machine learning-based Computational Model”, Eli Lilly and Company, March 20, 2000, Indianapolis, IN.

63. “Advancing Pharmacy through Research in the New Millenium” (keynote speaker), 7th Annual

Research Day, Univeristy of Missouri-Kansas City, May 9, 2000, Kansas City, MO.

64. “New Technologies for Advancing Drug Development and Discovery”, Society for the In Vitro Biology 2000 World Congress, June 2000, San Diego, CA.

65. “Predicting Human Drug Absorption Properties from In Vitro Data Using a Physiological-based

Computational Model”,(keynote speaker) Society for Biomedical Research, August 2000, Atlantic City, NJ.

Patrick J. Sinko, page 20 66. “Applications of Computational Tools for Predicting ADME Characteristics of Potential NCEs”,

Drug Discovery Technologies 2000 Meeting, August 2000, Boston, MA.

67. “In Silico Techniques for Predicting Absorption”, 3rd Annual International Conference on Drug Metabolism/Pharmacokinetics, September 2000, Madison, WI.

“Strategies and Technologies for the Oral Delivery of Peptide Therapeutics”, 68. Affymax Research Institute, October 2000, Palo Alto, CA . 69. Alza Corporation, October 2000, Mountain View, CA.

70. “Enabling Technologies for Ensuring Developability: Acquiring and Applying Screens for

ADME Properties to the Selections of Drug Candidates”, October 2000, AAPS Annual Meeting 2000, Indianapolis, IN.

71. “Strategies and Technologies of the Oral Delivery of Peptide Therapeutics”, December 2000,

Elan Pharmaceuticals, Dublin, Ireland.

72. “Strategies and Technologies for the Oral Delivery of Peptide Therapeutics”, 2001, Twenty-Second Annual Eino Nelson Memorial Conference, Captiva Island, Fl.

73. “Targeted Bioconjugates for Enhancing the Cell Uptake and Transport of Pharmaceutical

Macromolecules”, Johnson and Johnson Biomaterials Center, March 2001, Somerville, NJ.

74. “Delivering Pharmaceutical Macromolecules to Patients- A Technology for Enhanced Oral and Brain Uptake”, Pharmaceutical Biotechnology Session, Tech Trends Conference, April 2001, Atlantic City, NJ.

75. “The Role of Intestinal Secretion in the Oral Bioavailability of Anti-AIDS agents”, Clinical and

Pharmacologic Implications of Drug Transporters in HIV Therapy workshop Abbott Laboratories, April 2001, Abbott Park, IL.

76. “Delivering Pharmaceutical Macromolecules to Patients- A Technology for Enhanced Oral and

Brain Uptake”, Nobex Corporation, May 2001, Durham, NC.

77. “Targeted Bioconjugates for Enhancing the Cell Uptake and Transport of Pharmaceutical Macromolecules”, Bristol-Myers Squibb Pharmaceutical Research Institute, May 2001, Princeton, NJ.

78. “IVIVC Modeling Using Physiological Principles”, In Vitro-In Vivo Correlation Symposium

2001, sponsored by GloboMax Foundation, September 2001, Baltimore, MD.

79. “A Targeted Peptide-PEG-based Bioconjugation Approach For Enhancing the Bioefficacy of Pharmaceutical Macromolecules in AIDS and Cancer”, Pharmaceutical Engineering Open House 2001 Advisory Board Meeting, October 2001, Piscataway, NJ.

80. “My Experience with the AFPE/AACP New Investigator Grant and its Impact” American

Foundation for Pharmaceutical Education Board of Directors Meeting, January 2002, New York, NY.

Patrick J. Sinko, page 21 81. “Prospective Pharmacokinetic Modeling in Support of Drug Discovery” Graduate Program in

Pharmaceutical Science, Rutgers University, January 2002, Piscataway, NJ.

82. "Targeting cell surface receptors and transporters to enhance drug delivery in AIDS and Cancer”, Structural Genomics, Inc., February 2002, San Diego, CA.

83. “Budgeting Strategies for Federal Industrial, and other Sponsors” Research and Sponsored

Programs Grant Workshop Budgeting Basics: A Multi-Dimensional Approach, Rutgers University, May 2002, Piscataway, NJ.

84. “Tech Transfer and Start up Ventures - The Trials and Tribulations of a Modern Academic” at

the Center for Biomaterials Industrial Members Meeting, sponsored by the New Jersey Center for Biomaterials, Somerset Marriott Hotel, October 2002, Somerset, NJ.

85. “Targeted Drug Delivery Using Smart Biomaterials”, Syntonix Pharmaceuticals, Inc., October

2002, Waltham, MA.

86. “Molecular Biohparmaceutical Considerations of the First Pass Oral Loss of Saquinavir”, Hoffmann-La Roche, December 2002, Nutley, NJ.

87. “Targeted Macromolecular Drug Conjugates for Enhanced Cellular Uptake Disposition, and

Activity”, Molecular Biopharmaceutics Meeting, January 2003, Honolulu, Hawaii.

“Bioconjugate-Based Strategies For Enhancing Drug Uptake Into HIV-Sanctuary Sites” 88. Indiana University, School of Medicine, Indianapolis, IN January 2003. 89. Purdue University, School of Pharmacy, West Lafayette, IN January 2003.

“Targeted Bioconjugates for Enhanced Anti-HIV Bioefficacy” 90. St Johns University Jamaica NY April 9, 2003. 91. Elan Pharmaceuticals South San Francisco April 16, 2003. 92. University of Pennsylvania Philadelphia PA June 10, 2003.

93. “Molecular Considerations in the Oral Bioavailability of Anti-Aids Drugs”, Gilead Sciences Inc.,

June 2003, San Mateo, California.

94. “The Molecular and Cellular Processing of Drugs in the Gastrointestinal System” Genteric Incorporated workshop “Oral Gene Delivery for Protein Therapeutics, September 22-23, 2003, Berkley, CA.

95. "Strategies for Enhancing and Evaluating the Oral Delivery of Macromolecule Therapeutics",

Genteric Incorporated, November 3, 2003, Alameda CA.

96. “Role of MRPs in the Absorption and Disposition of Drugs”, Rutgers University Graduate School 50th Anniversary Conference, Piscataway, New Jersey, November 14, 2003.

“Molecular Biopharmaceutical Approaches for Enhancing Anti-HIV Drug Delivery” 97. University of Southern California, Keck School of Medicine, Los Angeles, CA, January 30,

2004. 98. University of Iowa, College of Pharmacy, Iowa City, IA, April 26, 2004.


99. “Advanced Drug Delivery Systems” Military Biomaterials Workshop, Center for Military

Biomaterials Research and the N J Center for Biomaterials, Iselin, NJ, February 2-4, 2004.

100. "Biopharmaceutics of HIV Therapy" National Meeting of the Woman’s Interagency HIV Study (WIHS), Rockville, M.D., May 10, 2004.

101. “The Role of Membrane Transporters and Drug Absorption and Uptake: Overview, Models and

Permeability” IBC Dug Transporters in Preclinical Development meeting, Boston MA, June 21-23.

102. “Dendrimers for Drug Delivery” USAMRIID-New Jersey Center for Biomaterials Meeting,

Piscataway, NJ, June 29th 2004.

“Biomaterial-based Cancer Drug Delivery - Macroscopic and Molecular Considerations” 103. University of Southern California, School of Pharmacy, Los Angeles, CA, September 24, 2004 104. Ohio State University, College of Pharmacy Columbus, Ohio, September 27, 2004.

105. “Biomaterial-based Drug Delivery in AIDS and Cancer” Hikma Pharmaceuticals, Amman,

Jordan, October 15, 2004.

106. “Targeted Drug Delivery Using Biomaterial-based Macromolecular Conjugates” Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, November 17, 2004.

“Mechanisms and Challenges of Metabolism and Transporter based Aids Boosting Therapy” 107. University of Southern California, Los Angeles, California, December 14, 2004. 108. State University of New York, Buffalo, New York, April 14, 2005.

109. “Methods for Assessing the Roles of Drug Transporters in Oral Absorption and Brain

Exposure” ADMET–2, San Diego, CA, February 10, 2005.

110. “Drug Transporters: Physiology, Design, and Application: I and II” Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, February 15, 2005.

111. “Intestinal and Brain Drug Transporters-Driving Forces and Impact on Absorption” 3rd World

Conference on Drug Absorption, Transport and Delivery, Barcelona, Spain, April 18, 2005. 112. “ Deciphering the Role of Drug Transporters in Early Drug Development: Cell Culture Models

and Approaches” Mid-Atlantic Regional Meeting, Rutgers University, New Brunswick NJ, May 23, 2005.

113. “Utilization of sRNA technology in transporter research” Sunrise School Session "Use of Novel

Experimental Techniques Drug Transporter Research, 2005 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, Nashville, Tennessee, November 8, 2005.

114. “PEG- Based fMLF Receptor Targeting Bioconjugates Enhance Binding to Phagocytic Cells”,

Second International Workshop on HIV Persistence during Therapy, French West Indies, December 6-9, 2005.

Patrick J. Sinko, page 23 115. “Nanotechnology: Hype, Hope and Targeted Drug Delivery”, 2006 Temple University

Distinguished Wyeth Research Lecture, Temple University, School of Pharmacy, Philadelphia, PA, April 20, 2006.

116. “The Promise of Nanotechnology in the Pharmaceutical Sciences” Susan Lehman Cullman

Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, May 2, 2006.

117. "Metronomic Chemotherapeutic Drug Regimens: Fighting Cancer Using "Ineffective" Dosages”

Labopharm Inc., Laval, Qc, October 13, 2006 118. “Predicting Oral Drug Absorption: Complex Situations, Complex Correlations” University of

Michigan, College of Pharmacy, Annual Science Symposium, Ann Arbor, Michigan, October 27, 2006.

119. “Role of Drug Transporters in Oral Bioavailability” session title “Role of Extrahepatic

Membrane Transporters in Drug Absorption Distribution and Excretion”, American Association of Pharmaceutical Scientists Annual Meeting and Exposition, San Antonio Texas, November 1, 2006.

120. "Targeted anti-HIV Therapy: A Molecular Drug Delivery Approach." University of Michigan,

College of Pharmacy, Ann Arbor, Michigan, November 7, 2006.

PUBLICATIONS (316) Research Articles: 92 Book and Textbook Chapters: 26 Books: 1 Published Abstracts: 197 Research Articles

1. Patrick J. Sinko, Ming Hu, and Gordon L. Amidon, “Carrier Mediated Transport of Amino Acids, Small Peptides and Their Drug Analogs”, Journal of Controlled Release, 6: 115-121, 1987.

2. M. Hu, P.J. Sinko, A.L.J. de Meere, D.A. Johnson, and G.L. Amidon, “Membrane permeability

parameters for some amino acids and ß-Lactam Antibiotics: Application of the Boundary Layer Analysis”, Journal of Theoretical Biology, 131: 107 – 114, 1988.

3. Patrick J. Sinko and Gordon L. Amidon, “Characterization of the Oral Absorption of ß-Lactam

Antibiotics I. Determination of Intrinsic Membrane Absorption Parameters in the Rat Small Intestine In Situ”, Pharmaceutical Research, 5: 645-650, 1988.

4. Gordon L. Amidon, Patrick J. Sinko, and David Fleisher, “Estimating Human Oral Fraction Dose

Absorbed: A Correlation Using Rat Intestinal Membrane Permeability for Passive and Carrier Mediated Compounds”, Pharmaceutical Research, 5: 651-654, 1988.

5. Patrick J. Sinko and Gordon L. Amidon, “Characterization of the Oral Absorption of ß-Lactam


Antibiotics II. Competitive Absorption and Peptide Carrier Specificity”, Journal of Pharmaceutical Sciences, 78: 723-727, 1989.

6. Hsiao-Hwa Lu, Patrick J. Sinko, and David Fleisher, “Fed-State Zidovudine Absorption”, AIDS, 5:907-908, 1991.

7. Patrick J. Sinko, Glen D. Leesman and Gordon L. Amidon, “Predicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach”, Pharmaceutical Research, 8: 979-988, 1991.

8. Patrick J. Sinko, “Intestinal Absorption of Peptides and Peptide-Analogs: Implications of Fasting Serine Protease Levels and pH on the Extent of Oral Absorption in Dogs and Humans”, Pharmaceutical Research, 9: 316-321, 1992.

9. Doo-Man Oh, Patrick J. Sinko and Gordon L. Amidon, “Characterization of the Oral Absorption of Several Aminopenicillins: Determination of Intrinsic Membrane Absorption Parameters in the Rat Intestine In Situ”, International Journal of Pharmaceutics, 85: 181-187, 1992.

10. P.J. Sinko, G.D. Leesman and G.L. Amidon, “Mass Balance Approaches for Predicting the Intestinal Absorption and Metabolism of Peptides and Analogs: Theoretical Development and Applications”, Pharmaceutical Research, 10: 271-275, 1993.

11. Doo-Man Oh, Patrick J. Sinko and Gordon L. Amidon, “Characterization of the Oral Absorption of Some ß-lactams: Structural Requirement of the Peptide Transport of ß-lactam Antibiotics for an α-amino Group on the Side Chain”, Journal of Pharmaceutical Sciences, 82: 897- 900, 1993.

12. Patrick J. Sinko, Nisha R. Patel and Peidi Hu, “Site-Specific Oral Absorption of Didanosine: In Situ Characterization and Correlation with Extent of Absorption In Vivo”, International Journal of Pharmaceutics, 109: 125-133, 1994.

13. Patrick J. Sinko, Peidi Hu, Anthony P. Waclawski and Nisha R. Patel, “Oral Absorption of Anti-AIDS Nucleoside Analogues: 1. Intestinal Transport of Didanosine in Rat and Rabbit Preparations”, Journal of Pharmaceutical Sciences, 84: 959-965, 1995.

14. P.J. Sinko, C.L. Smith, L. McWhorter, W. Stern, E. Wagner and J.P. Gilligan, “Utility of Pharmacodynamic Measures in Assessing Oral Bioavailability of Peptides. 1. Administration of Recombinant Salmon Calcitonin in Rats”, Journal of Pharmaceutical Sciences, 84: 1374-1378, 1995.

15. Patrick J. Sinko and Peidi Hu, “Determining Intestinal Metabolism and Permeability for Several Compounds in Rats: Implications on Regional Bioavailability in Humans”, Pharmaceutical Research, 13:108-113, 1996.

16. Patrick J. Sinko, Glen D. Leesman, Anthony P. Waclawski and Jim H. Kou, “Analysis of Intestinal Perfusion Data for Highly Permeable Drugs Using a Numerical Aqueous Resistance - Nonlinear Regression Method”, Pharmaceutical Research, 13: 570-576, 1996.

17. Anthony P. Waclawski and Patrick J. Sinko, “Oral Absorption of Anti-AIDS Nucleoside Analogues. 2. Carrier-Mediated Absorption of Stavudine in Rat and Rabbit Preparations”,


Journal of Pharmaceutical Sciences, 85: 478-485, 1996.

18. Daniel A. Norris and Patrick J. Sinko, “Effect of Size, Surface Charge, and Hydrophobicity on the Uptake and Translocation of Polystyrene Microspheres Through Gastrointestinal Mucin”, Journal of Applied Polymer Science, 63: 1481-1492, 1997.

19. Hongshi Yu, Thomas J. Cook, and Patrick J. Sinko, “Evidence for Diminished Functional Expression of Intestinal Transporters in Caco-2 Cell Monolayers at High Passages”, Pharmaceutical Research, 14: 757-762, 1997.

20. Patrick J. Sinko, J.P. Sutyak, P. Hu, G.D. Leesman, V. Makhey, H. Yu and C.L. Smith, “Oral Absorption of Anti-AIDS Nucleoside Analogues: 3. Regional Intestinal Absorption and In Vivo Permeability of 2',3'-Dideoxyinosine in an Intestinal-Vascular Access Port (IVAP) Dog Model”, Biopharmaceutics and Drug Disposition 18: 697-710, 1997.

21. Hongshi Yu and Patrick J. Sinko, “Influence of the Microporous Substratum and Resistances to Drug Transport in Cell Culture Systems: Calculation of Intrinsic Transport Parameters”, Journal of Pharmaceutical Sciences, 86: 1448-1457, 1997.

22. Patrick J. Sinko and Praveen Balimane, “Carrier-Mediated Intestinal Absorption of Valacyclovir, the L-Valyl Ester Prodrug of Acyclovir: 1. Interaction with Peptides, Organic Anions, and Organic Cations In Rats”, Biopharmaceutics and Drug Disposition, 19: 209-217, 1998.

23. Vijaya D. Makhey, Ailan Guo, Daniel Norris, Peidi Hu, Jiansheng Yan, and Patrick J. Sinko, “Characterization of the Regional Intestinal Kinetics of Drug Efflux in Rat and Human Intestine and in Caco-2 Cells”, Pharmaceutical Research, 15: 1160 – 1167, 1998.

24. P.V. Balimane, I. Tamai, A. Guo, T. Nakanishi, H. Kitada, F.H. Leibach, A. Tsuji, and P.J. Sinko, “Direct Evidence for Peptide Transporter (PepT1)-mediated Uptake of a Nonpeptide Prodrug, Valacyclovir”, Biochemical and Biophysical Research Communications, 250: 246-251, 1998.

25. Daniel A. Norris, Navneet Puri, and Patrick J. Sinko, “The Effects of Barriers and Properties on the Oral Absorption of Particulates”, Advanced Drug Delivery Reviews, 34: 135-154, 1998.

26. Guo A., P. Hu, P.V. Balimane, F.H. Leibach, and P.J. Sinko, “Interactions of a Nonpeptidic Drug, Valacyclovir, with the Human Intestinal Peptide Transporter (hPepT1)”, Journal of Pharmacology and Experimental Therapeutics, 289: 448 – 454, 1999.

27. P. J. Sinko, Y.H. Lee, V. D. Makhey, G. D. Leesman, J. P. Sutyak, H. Yu, B. Perry, C. L. Smith, P. Hu, E. J. Wagner, L. Falzone, L. McWhorter, J. P. Gilligan, and W. Stern, “Biopharmaceutical Approaches for Developing and Assessing Oral Peptide Delivery Strategies and Systems. 1. Recombinant Salmon Calcitonin (sCT)”, Pharmaceutical Research, 16: 527 – 533, 1999.

28. Daniel A. Norris, Navneet Puri, Mohamed E. Labib, and Patrick J. Sinko, “Determining the Absolute Surface Hydrophobicity of Microparticles Using Thin Layer Wicking”, Journal of Controlled Release, 59: 173 – 185, 1999.

29. Yong-Hee Lee, Barbara Perry, Stacy LaBruno, Hee Sang Lee, William Stern, Lisa M. Falzone,


and Patrick J. Sinko, “The Impact of Regional Intestinal pH Modulation on the Absorption of a Model Peptide Drug, Salmon Calcitonin in Beagle Dogs”, Pharmaceutical Research, 16: 1233 – 1239, 1999.

30. Praveen V. Balimane and Patrick J. Sinko, “The Involvement of Multiple Transporters in the Oral Absorption of Nucleoside Analogues”, Advanced Drug Delivery Reviews, 39: 183 – 210, 1999.

31. Gregory C. Williams and Patrick J. Sinko, “Oral Absorption of the HIV Protease Inhibitors: A Current Update”, Advanced Drug Delivery Reviews, 39: 211 – 238, 1999.

32. Yong-Hee Lee, Barbara Perry, John P. Sutyak, William Stern, and Patrick J. Sinko, “Regional Differences in Intestinal Spreading and pH Recovery on the Effectiveness of Pharmaceutical Excipients and the Impact on Salmon Calcitonin Absorption in Beagle Dogs”, Pharmaceutical Research, 17: 284-290, 1999.

33. Elora Gupta, Feng Luo, Anita Lalloo, Srinivasan Ramanathan, Viral Vyas, Eric Rubin and Patrick Sinko, “The Intestinal Absorption of Camptothecin a Highly Lipophilic Drug Across Caco-2 Cells is Mediated by Active Transporter(s)”, Anticancer Research, 20: 1013-1016, 2000.

34. Daniel Norris, G.D. Leesman, P.J. Sinko and G.M. Grass, “Development of Predictive Pharmacokinetics Simulation Models for Drug Discovery”, Journal of Controlled Release, 65: 55-62, 2000.

35. N. Puri, E.H. Weyand, S.M. Abdel-Rahman and P.J. Sinko, “An Investigation of Intradermal Route as an Effective Means of Immunization for Microparticulate Vaccine Delivery Vehicles”, Vaccine, 18: 2600-2612, 2000.

36. Yong Hee Lee, Glen D. Leesman, Vijaya Makhey, Hongshi Yu, Peidi Hu, Barbara Perry, John P. Suytak, Erik J. Wagner, Lisa M. Falzone, William Stern and Patrick J. Sinko, “Regional Oral Absorption, Hepatic First-Pass Effect, and Non-Linear Disposition of Salmon Calcitonin in Beagle Dogs”, European Journal of Pharmaceutics and Biopharmaceutics, 50: 205-211, 2000.

37. Yong-Hee Lee, John P. Sutyak, Barbara Perry, William Stern, Vijaya D. Makhey, and Patrick J. Sinko, “Improved Longevity and Functionality of a Canine Model Providing Portal Vein and Multi-Site Intestinal Access”, Comparative Medicine, 50: 167-174, 2000.

38. Yong Hee Lee and Patrick J. Sinko, “Oral Delivery of Salmon Calcitonin”, Advanced Drug

Delivery Reviews, 42: 225-238, 2000

39. Elora Gupta, Viral Vyas, Farheena Ahmed, Patrick Sinko, Thomas Cook, and Eric Rubin, “Pharmacokinetics Of Orally Administered Camptothecins”, Ann NY Acad Sci, 922: 195-204, 2000.

40. Praveen V. Balimane and Patrick J. Sinko, “Effect of Ionization on the Variable Uptake of Valacyclovir Via the Human Intestinal Peptide transporter (hPepT1) in CHO cells”, Biopharmaceutics and Drug Disposition, 21: 165-174, 2000.

41. Jeevan Kunta, Jiansheng Yan, Vijaya D. Makhey, and Patrick J. Sinko, “Active Efflux of


Etoposide from Rabbit Small Intestine and Colon”, Biopharmaceutics and Drug Disposition, 21: 83-93, 2000.

42. N. Puri, and Patrick J. Sinko, “Adjuvancy Enhancement of Muramyl Dipeptide By Modulation Its Release From a Physiocochemically Modified Matrix of Ovalbumin Microspheres. II. In Vivo Investigation”, Journal of controlled Release, 69: 69-80, 2000.

43. N. Puri, J.H. Kou, and Patrick J. Sinko, “Adjuvancy Enhancement of Muramyl Dipeptide By Modulation Its Release From a Physiocochemically Modified Matrix of Ovalbumin Microspheres. I. In Vitro Characterization”, Journal of Controlled Release, 69: 53-67, 2000.

44. George M. Grass and Patrick J. Sinko, “Effect of diverse datasets on the predictive capability of ADME models in drug discovery”, Drug Discovery Today, 6 (HTS Suppl): S158 - S165, 2001.

45. Navneet Puri, Satish K. Pejaver, Pankaj Paranjpe, and Patrick J. Sinko, “Bioavailability of Parenteral Products”, U.S. Pharmacist, 26: HS 41-52, 2001.

46. Srinivasan Ramanathan, Bo Qiu, Shahriar Pooyan, Guobao Zhang, Stanley Stein, Michael J.

Leibowitz, and Patrick. J. Sinko, “Targeted PEG-Based Bioconjugates Enhance the Cellular Uptake and Transport of an HIV-1 Tat Nonapeptide”, Journal of controlled Release, 77:199-212, 2001.

47. Yong-Hee Lee, Barbara A. Perry, Hee-Sang Lee, Jeevan R. Kunta, John P. Sutyak, and Patrick J. Sinko, “Differentiation of Gut and Hepatic First-Pass Effect of Drugs: 1. Studies of Verapamil in Ported Dogs”, Pharmaceutical Research, 18: 1721-1728, 2001.

48. Jeevan R. Kunta Barbara A. Perry, John P. Sutyak, and Patrick J. Sinko, “Development of a Novel Intestinal and Vascular Access Port (IVAP) Rabbit Model to Study the Regio-Specific Oral Absorptive Pharmacokinetics of Drugs”, Comparative Medicine, 51: 349-356, 2001.

49. Matthew M. Hoffmann, Patrick J. Sinko, Robert J. Meeker and Robert Snyder, “Pharmacokinetics of Benzene Following an Oral or Intradermal Dose in FVB and Tg.AC Mice”, Adv. Exp. Med. Biol., 500: 455-458, 2001.

50. Matthew M. Hoffmann, Patrick J. Sinko. Yong-Hee Lee, Robert J. Meeker and Robert Snyder. “Pharmacokinetic Studies in Tg.AC and FVB Mice Administered [C] Benzene either by Oral Gavage or Intradermal Injection”, Toxicology and Applied Pharmacology, 174: 139-145, 2001.

51. S. Ramanathan, S. Pooyan, S. Stein, P.D. Prasad, J. Wang, M.J. Leibowitz, V. Ganapathy and P.J. Sinko, “Targeting the Sodium-Dependant Multivitamin Transporter (SMVT) for Improving the Oral Absorption Properties of a Retro-Inverso Tat Nonapeptide”, Pharmaceutical Research, 18: 950-956, 2001.

52. Shahriar Pooyan, Bo Qiu, Marion M. Chan, Dunne Fong, Patrick J. Sinko. Michael L. Leibowitz

and Stanley Stein, “Conjugates Bearing Multiple Formyl-Methionyl Peptides Display Enhanced Binding to but Not Activation of Phagocytic Cells”, Bioconjugate Chemistry, 13:216-223, 2002.

53. George M. Grass and Patrick J. Sinko, “Physiologically-Based Pharmacokinetic Simulation


Modeling”, Advanced Drug Delivery Reviews, 54:433-451, 2002.

54. Ailan Guo, William Marinaro, Peidi Hu and Patrick J. Sinko, “Delineating The Contribution of Secretory Tansporters in the Efflux of Etoposide Using MDCK Cells Overexpressing Pgp, MRP1 and cMOAT”, Drug Metabolism and Disposition, 30:457- 463, 2002.

55. Feng R. Luo, Pankaj V. Paranjpe, Ailan Guo, Eric Rubin, and Patrick J. Sinko, “Intestinal

Transport of Irinotecan in Caco-2 Cells and MDCK II Cells over expressing Efflux Transporters PGP, cMOAT, and MRP1”, Drug Metabolism and Disposition, 30:763-770, 2002.

56. Tamara Minko, Pankaj Paranjpe, Bo Qiu, Anita Lalloo, Roney Won, Stanley Stein, and Patrick J. Sinko, “Enhancing the Anticancer Efficacy of Camptothecin using Biotinylated Poly(ethylene glycol) Conjugates in Sensitive and Multidrug Resistant Human Ovarian Carcinoma Cells”, Cancer Chemotherapy and Pharmacology, 50: 143-150, 2002.

57. Gregory C. Williams, Angela Liu, Gregory Knipp and Patrick J. Sinko, “Direct Evidence That Saquinavir is Transported by Multidrug Resistance-Associated Protein (MRP1) and Canalicular Multispecific Organic Anion Transporter (MRP2)", Antimicrobial Agents and Chemotherapy, 46: 3456-3462, 2002.

58. Bo Qiu, Simon Stefanos, Jianglin Ma, Anita Lalloo, Barbara A. Perry, Michael J. Leibowitz, Patrick J. Sinko and Stanley Stein, “A Hydrogel Prepared By In Situ Cross-Linking of A Thiol-Containing Poly(ethylene glycol)-Based Copolymer: a New Biomaterial for Protein Drug Delivery”, Biomaterials, 24: 11-18, 2003.

59. Guobao Zhang, Michael J. Leibowitz, Patrick J. Sinko and Stanley Stein, “Multiple-Peptide

Conjugates for Binding B-Amyloid Plaques of Alzheimers Disease”, Bioconjugate Chemistry, 14: 86-92, 2003.

60. Helen H. Usansky and Patrick J. Sinko, “Computation of LogBB Values for Compounds Transported Through Carrier-Mediated Mechanisms Using in-vitro Permeability Data from Brain Microvessel Endothelial Cell (BMEC) Monolayers”, Pharmaceutical Research, 20: 390-396, 2003.

61. Rajeev Rajendra, Murugesan K. Gounder, Ahamed Saleem, Jan H. M. Schellens, Douglas D. Ross, Susan E. Bates, Patrick Sinko, and Eric H. Rubin, “Differential Effects of the Breast Cancer Resistance Protein on the Cellular Accumulation and Cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin”, Cancer Research, 63: 3228-3223, 2003.

62. K-J. Lee, R. Mower, T. Hollenbeck, J. Castelo, N. Johnson, P. Gordon, P.J. Sinko, K. Holme and Y. Lee, “Modulation of Non-Specific Binding in Ultrafiltration Protein Binding Studies”, Pharmaceutical Research, 20: 1015-1021, 2003.

63. Gregory C. Williams, Gregory T. Knipp and Patrick J. Sinko, “The Effect of Cell Culture Conditions On Saquinavir Transport and Interactions using MDCKII Cells Overexpressing hMDR1”, Journal of Pharmaceutical Science, 92: 1957-1976, 2003.

64. S. S. Dharap, B. Qiu, G. C. Williams, P. Sinko, S. Stein, T. Minko, “Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptide”, Journal of Controlled Release,


91:61-73, 2003.

65. Pankaj V. Paranjpe and Patrick J. Sinko, “Overcoming Paracellular Tissue Barriers for Drug Delivery”, Pharmaceutical News, 9: 381-395, 2003.

66. Jungil Hong, Joshua D. Lambert, Sung-Hack Lee, Patrick J. Sinko, and Chung S. Yang, “Involvement of Multidrug Resistance-Associated Proteins in Regulating Cellular Levels of (-)-Epigallocatechin-3-Gallate and Its Methyl Metabolites”, Biochem. Biophys. Res. Comm., 310: 222-227, 2003.

67. Pankaj Paranjpe, George M. Grass and Patrick J. Sinko, “Insilico Tools for Drug Absorption Prediction: Experience to date”, American Journal of Drug Delivery, 1: 133-148, 2003.

68. Jeevan Kunta and Patrick J. Sinko, “Intestinal Drug Transporters: In Vivo Function and Clinical Importance”, Current Drug Metabolism, 1: 109-24, 2004.

69. Yaming Su, Xiaoping Zhang and Patrick J. Sinko, “Human Organic Anion Transporting Polypeptide OATP-A (SLC21A3) Acts in Concert with P-glycoprotein (Pgp) and Multidrug Resistance Protein 2 (MRP2) in the Vectorial Transport of Saquinavir in HepG2 Cells”, Molecular Pharmaceutics, 1: 49-56, 2004.

70. Xiaoping Zhang, Li Wan, Shahriar Pooyan, Yaming Su, Carol R., Gardner, Michael J. Leibowitz, Stanley Stein and Patrick J. Sinko, “Quantitative Assessment Of The Cell Penetrating Properties Of R.I.-Tat-9: Evidence For A Cell Type-Specific Barrier At The Plasma Membrane Of Epithelial Cells”, Molecular Pharmaceutics, 1: 145-155, 2004.

71. Jeevan Kunta, Helen Usansky, Barbara Perry, and Patrick J. Sinko, “Differentiation of the Gut and Hepatic First-Pass Metabolism and Secretion of Saquinavir in Ported Rabbits”, Journal of Pharmacology and Experimental Therapeutics, 310: 359-366, 2004.

72. Anita Lalloo, Feng R. Luo, Ailan Guo, Pankaj Paranjpe, Sung-Hack Lee, Viral Vyas, Eric Rubin, and Patrick J. Sinko. “Membrane Transport of Camptothecin is Facilitated by Human P-glycoprotein (ABCB1) and Multidrug Resistance Protein 2 (ABCC2)”, BMC Medicine, 2:16, 2004.

73. Yaming Su, Sung-Hack Lee and Patrick J. Sinko, “Practical Aspects of Transporter Model Systems: A Case Study Involving Saquinavir”, Drug Metabolism Reviews, 36: 377-389, 2004.

74. Guobao Zhang, Bo Qui, Barbara Perry, Denise E. Georgopoulos Michael J. Liebowitz, Patrick J. Sinko and Stanley Stein. “Bioreversible Disulfide Linkage of Thiomide Compounds to ThiolPoly (ethylene glycol): Application to UC781, an Inhibitor of HIV-1 Reverse Transcriptase”, Journal of Applied Therapeutic Research, 4: 46-53, 2004.

75. J.R. Kunta, Sung-Hack Lee, B.A. Perry, Y. H. Lee, and P.J. Sinko, “Differentiation of Gut and Hepatic First-Pass Loss of Verapamil in Intestinal and Vascular Access-Ported (IVAP) Rabbits”, Drug Metabolism and Disposition, 32: 1293-1298, 2004.

76. Pankaj V. Paranjpe, Yu Chen, Vladyslav Kholodovych,William Welsh, Stanley Stein and Patrick J. Sinko, "Tumor Targeted Bioconjugate Based Delivery of Camptothecin: Design, Synthesis


and In Vitro Evaluation", Journal of controlled Release, 100: 275-292, 2004.

77. Simi Gunaseelan, Olivia Debrah, Li Wan, Michael J. Leibowitz, Arnold B. Rabson, Stanley Stein and Patrick J. Sinko, “Synthesis of Poly(Ethylene Glycol) -Based Saquinavir Prodrug Conjugates and Assessment of Release and Anti-HIV-1 Bioactivity Using a Novel Protease Inhibition Assay”, Bioconjugate Chemistry, 15: 1322-1333, 2004.

78. Seonghee Park and Patrick J. Sinko, “P-Glycoprotein And Mutlidrug Resistance Associated Proteins Limit The Brain Uptake Of Saquinavir In Mice”, Journal of Pharmacology and Experimental Therapeutics, 312:1249-1256, 2005.

79. Fanfan Zhou, Wen Xu, Mei Hong, Zui Pan, Patrick J. Sinko, Jianjie Ma, and Guofeng You, “The role of N-linked glycosylation in protein folding, membrane targeting and substrate binding of human organic anion transporter hOAT4”, Molecular Pharmacology, 67:868-876, 2005.

80. Kyoung-Jin Lee, Nikole Johnson, Jesus Castelo, Patrick J. Sinko, George Grass, Kevin Holme, and Young-Hee Lee, “Effect of Experimental pH on the Permeability in Rabbit Intestines and Caco-2 Monolayers”, European Journal of Pharmaceutical Sciences, 25:193-200, 2005.

81. S.S. Dharap, Y. Wang, P.Chandna, J. J. Khandare, B. Qiu, S. Gunaseelan, P. J. Sinko, S. Stein A. Farmanfarmaian, and T. Minko, “Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide”, Proceedings of the National Academy of Science, 6:12962-12967, 2005.

82. Helen H. Usansky and Patrick J. Sinko, “Estimating Human Drug Oral Absorption Kinetics From Caco-2 Permeability Using an Absorption-Disposition Model: Model Development and Evaluation and Derivation of Analytical Solutions for ka and Fa”, Journal of Pharmacology and Experimental Therapeutics, 314: 391-399, 2005.

83. Pankaj V. Paranjpe, Stanley Stein and Patrick J. Sinko, "Tumor-Targeted and Activated Bioconjugates for Improved Camptothecin Delivery", Anti-Cancer Drugs, 16: 763-775, 2005.

84. Rajinder K Bhardwaj, Dea Herrera-Ruiz, Patrick J. Sinko, Olafur S. Gudmundsson and Gregory Knipp, “Delineation Of hPepT1 Mediated Uptake And Transport Of Substrates With Varying Transporter Affinities Utilizing Stably Transfected Hpept1/Mdck Clones And Caco-2 Cells”, Journal of Pharmacology and Experimental Therapeutics, 314: 1093-1100, 2005.

85. Seonghee Park And Patrick J. Sinko, “The Blood-Brain Barrier Sodium-Dependent Multivitamin Transporter (Smvt): A Molecular Functional In Vitro - In Situ Correlation”, Drug Metabolism and Disposition, 33: 1547–1554, 2005.

86. Li Wan, Simi Gunaseelan, Shahriar Pooyan, Olivia Debrah, Xiaoping Zhang, Michael J. Leibowitz, Arnold B. Rabson, Stanley Stein and Patrick J. Sinko, “Novel Multi-component nanopharmaceuticals derived from poly(ethylene) glycol bioconjugates, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects”, AIDS Research and Therapy, doi:10.1186/1742-6405-3-12, 3:12, 2006.

87. Pankaj V. Paranjpe and Patrick J. Sinko, “Programmed and Tumor-Targeted Delivery of Anticancer Drugs Using Macromolecular Bioconjugates”, American Pharmaceutical Review, 1-


5, 2006.

88. S.H. Lee and P.J. Sinko, “siRNA – Getting the message out”, Theme issue - Drug Transporters: Integration in Understanding ADME, European Journal of Pharmaceutical Sciences, 27: 401-410, 2006.

89. J. Polli and P. Sinko, “Preface”, Theme issue - Drug Transporters: Integration in Understanding ADME, European Journal of Pharmaceutical Sciences, 27: 391, 2006.

90. Yaming Su and Patrick J. Sinko, “Drug Delivery Across the Blood-Brain-Barrier: Why Is It

Difficult? How to Measure and Improve It?”, Expert Opinion on Drug Delivery, 3: 419-435, 2006.

91. Anita Lalloo, Piyun Chao, Peidi Hu, Stanley Stein and Patrick Sinko “Pharmacokinetic And

Pharmacodynamic Evaluation Of A Novel In Situ Forming Poly(Ethylene Glycol)-Based Hydrogel For The Controlled Delivery Of The Camptothecins”, Journal Of Controlled Release, 112: 333-342, 2006.

92. Yaming Su, Ziaoping Zhang, Sung-Hack Lee and Patrick J. Sinko, “Inhibition Of Efflux

Transporter ABCG2/BCRP Does Not Restore Mitoxantrone Sensitivity In Irinotecan-Selected Human Leukemia CPT-K5 Cells”, European Journal of Pharmaceutical Sciences, 29: 102-110, 2006.

93. Yaming Su, Xiaoping Zhang, Patrick J. Sinko, “Exploitation of drug-induced Bcl-2

overexpression for restoring normal apoptosis function: A promising new approach to the treatment of multidrug resistant cancer”, Cancer Letters, accepted January 2007.

Manuscripts Submitted or in preparation. 1. Helen H. Usansky and Patrick J. Sinko,“Differential Roles of Pgp, Mrp2 and CYP3A in

“Boosting” the Pharmacokinetics of Saquinavir Following Oral Administration to Sprague-Dawley Rats”, Drug Metabolism and Disposition, resubmitted September 2006.

2. Anita K Lalloo, Stanley Stein and Patrick Sinko, “Characterization Of A Novel In Situ

Forming Poly(Ethylene Glycol)-Based Hydrogel”, European Journal of Pharmaceutics, submitted December 2005, in revision.

3. Yaming Su, P. Hu, Sung-hack Lee, Patrick J. Sinko, “The role of intestinal breast cancer

resistant protein (BCRP) in the absorption and disposition of topotecan (TPT)”, Drug Metabolism and Disposition, submitted November 2006.

4. Xiaoping Zhang, Yongjiu Jin, Shahriar Pooyan, Simi Gunaseelan, Li Wan, and Patrick J.

Sinko, “R.I.-CKTat9, a cell penetrating peptide, enters Hela cell through the clathrin-mediated endocytosis, not direct plasma membrane penetration.” Molecular Pharmaceutics, submitted January 30, 2007.

Patrick J. Sinko, page 32 5. Pi-Yun Chao, Stanley Stein, Patrick J. Sinko, “Polyethylene Glycol Enhances The Pulmonary

Passive Targeting And Retention Of Microspheres In Rats”, Journal of controlled Release, in preparation.

6. Pi-Yun Chao, Stanley Stein, Patrick J. Sinko, “Camptothecin Ester Prodrugs Consisted Of A

Series Of Amino Acids With Linear Side Chains – In Vitro Hydrolysis And Cytotoxicity In Human Lung Carcinoma Cells”, in preparation.

7. Pi-Yun Chao, Stanley Stein, and Patrick J. Sinko, “A Parenterally-administered, passively

targeted pulmonary drug delivery system with enhanced retention properties: Anti-cancer evaluation in an orthotopic lung cancer rat model”, in preparation.

8. Xiaoping Zhang and Patrick Sinko, “R.I.-Tat-9, A Cell Penetrating Peptide (CPP), Uses Two

Coexisting Pathways To Enter Cells”, Molecular Pharmaceutics, in preparation. 9. Li Wan, Matthew Palombo, Xaioping Zhang, Shahriar Pooyan, Pei-Ming Chen, Stanley Stein,

and Patrick J. Sinko, “Design, Synthesis And Evaluation Of Multi-Valent Macrophage-Targeted Peg-Fmlf (N-Formyl-Methionyl-Leucyl-Phenylalanine) Conjugates: Pharmacokinetics And Biodistribution in Rats”, in preparation.

10. Li Wan, Matthew Palombo, Xaioping Zhang, Shahriar Pooyan, Pei-Ming Chen, Stanley Stein,

and Patrick J. Sinko, “Biopolymer-based Targeting Using PEG-fMLF (N-formyl-methionine-leucine-phenylalanine) Conjugates Improves Macrophage Uptake by Increasing Avidity”, in preparation.

11. Shahriar Pooyan, Simi Gunaseelan, Stanley Stein and Patrick J. Sinko, “Synthesis and

characterization of peptide-based PEGylated fMLF nanocarriers”, in preparation. 12. Shahriar Pooyan, Simi Gunaseelan, Olivia Debra, Xaioping Zhang, Stanley Stein, and Patrick

J. Sinko, “Antiviral activity of PEG-based Saquinivar conjugates”, in preparation. 13. Pei-Ming Chen, Shahriar Pooyan, Xaioping Zhang, Stanley Stein, and Patrick J. Sinko,

“Synthesis and cellular uptake analysis of Mannose-targeted nanocarriers: Effect of Copy Number (Avidity)”, in preparation.

Books, Reviews, and Contributed Chapters (26) 1. Patrick J. Sinko, Cefadroxil (monograph), in: Chemical Stability of Pharmaceuticals, Second

Edition, K.A. Connors, G.L. Amidon, and V.J. Stella, (editors). John Wiley and Sons, Inc., New York, (1986), 295-301.

2. Glen D. Leesman, Patrick J. Sinko, and Gordon L. Amidon "Simulation of Oral Drug

Absorption: Gastric Emptying and GI Motility Considerations" in: Pharmacokinetics - Regulatory, Industrial, and Academic Perspectives. Peter G. Welling and Francis L. Tse (editors), Marcel Dekker, Inc. (New York), 1988, Ch. 6, p. 267.

3. Gordon L. Amidon, Glen D. Leesman Patrick J. Sinko and Ming Hu, "Design of Prodrugs for

Oral Drug Delivery" Proceedings of the Second International ISSX Meeting, (Kobe, Japan, May 1988) R.W. Estabrook and M.N. Cayens, Eds., Taylor & Francis Ltd., Great Britain, 1989


pp 117-124. 4. Gordon L. Amidon, Patrick J. Sinko, Ming Hu and Glen D. Leesman, "Absorption of Difficult

Drug Molecules; Carrier-Mediated Transport of Peptides and Peptide Analogs", in: Novel Drug Delivery and its Therapeutic Application, L.F. Prescott and W.S. Nimmo, Eds., John Wiley & Sons Ltd., Great Britain (1989).

5. Doo-Man Oh, Patrick J. Sinko and Gordon L. Amidon, "Predicting Oral Drug Absorption in

Humans: A Macroscopic Mass Balance Approach for Passive and Carrier-Mediated Compounds", in: "Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Modeling" D.Z. D'Argenio, Ed., Plenum Press, New York pp 3-11 (1991).

6. Gordon L. Amidon, Patrick J. Sinko and Maureen D. Donovan, "Oral Absorption of Peptides and

Peptide-type Drugs: Problems and Prospects" in: Peptides, Theoretical and Practical Approaches to Their Delivery, Capsugel Symposia Series, Capsugel Library, pp 21-26 (1992).

7. Patrick Sinko and Joachim Kohn, "Polymeric Drug Delivery Systems - An Overview" in

Polymer Delivery Systems. M. El-Nokaly, D. Piatt and B. Charpentier, Eds., American Chemical Society Books, Washington, D.C., 18-41 (1993).

8. Patrick J. Sinko, “Release Rate and In vivo Dissolution Rate : Impact on IVIVC” in Scientific

Foundations for Regulating Drug Product Quality, G.L. Amidon, J.R. Robinson, and R.L. Williams, eds., American Association of Pharmaceutical Scientists Press, Alexandria, VA pp.293-304 (1997).

9. Patrick J. Sinko, Screening Acceptable Pharmacokinetic Qualities in Early Drug Discovery in

Current Opinions in Drug Discovery & Development : The Chemistry of Metabolic & Toxicological Processes. D. Johnson and D. Smith, Eds. Current Drugs, Ltd, London pp. 42-48 (1999).

10. Y. Lee, G. Scucci and P.J. Sinko Non-Invasive Peptide and Protein Delivery in Encyclopedia of

Pharmaceutical Technology, Marcel Dekker, New York (2000). 11. Sung-Hack Lee, Yaming Su, Seonghee Park and Patrick J. Sinko, In Vitro Permeation Study

with Bovine Brain Microvessel Endothelial Cells, Optimization in Drug Discovery: in Vitro Methods, Humana Press, New Jersey (2004).

12. Yaming Su and Patrick J. Sinko, Evaluation of Drug-Transporter Interactions Using in vitro Cell

Models, Optimization in Drug Discovery: in Vitro Methods, Humana Press, New Jersey (2004). Patrick J. Sinko (Editor), Martin’s Physical Pharmacy and Pharmaceutical Sciences Fifth Edition, Lippincott Williams and Wilkins, ISBN: 0-7817-5027-X, Baltimore MD (2006).

Major revisions or completely new chapters in Martin authored by Sinko: 13. Chapter 1, Introduction 14. Chapter 5, Nonelectrolytes 15. Chapter 6, Solutions of Electrolytes 16. Chapter 7, Ionic Equilibria 17. Chapter 8, Electromotive Force and Oxidation-Reduction


18. Chapter 9, Buffered and Isotonic Solutions 19. Chapter 10, Solubility and Distribution Phenomena 20. Chapter 11, Complexation and Protein Binding 21. Chapter 12, Diffusion 22. Chapter 13, Drug Release and Dissolution 23. Chapter 14, Biopharmaceutics 24. Chapter 15, Chemical Kinetics and Stability 25. Chapter 18, Coarse Dispersions 26. Chapter 19, Micromeritics

Published Abstracts. 1. Sinko, P.J. and Amidon G.L., Characterization of the Oral Absorption of beta-Lactam

Antibiotics. Peptide Carrier Specificity and Determination of Intrinsic Membrane Absorption Parameters, Pharmaceutical Research, 3(suppl): 93S, 1986, Washington, D.C.

2. P.J. Sinko, G.D. Leesman, and G.L. Amidon, Utilization of In Situ Membrane Absorption

Parameters to Simulate beta-lactam Antibiotic Plasma Levels, Pharmaceutical Research, 4(suppl): S-44, (1987), Boston, MA.

3. Gordon L. Amidon and Patrick J. Sinko, Oral Absorption of Passive and Carrier Mediated

Compounds. Correlation of Permeability and Fraction of Dose Absorbed, in: P.I. Lee and B.A. Leonhardt, editors, Proceedings of the 14th International Symposium on Controlled Release of Bioactive Materials", Controlled Release Society, Inc., Lincolnshire, IL, pp. 20-21, 1987, Toronto, Ontario Canada.

4. Gordon L. Amidon, Patrick J. Sinko, and Glen D. Leesman, Macroscopic Mass Balance

Approach For Predicting Fraction Dose Absorbed in Humans", in: P.I. Lee and B.A. Leonhardt, editors, Proceedings of the 15th International Symposium on Controlled Release of Bioactive Materials, Controlled Release Society, Inc., Lincolnshire, IL, 1988 Basel, Switzerland.

5. G.L. Amidon, P.J. Sinko, M. Hu, and G.D. Leesman, Absorption of Difficult Drug

Molecules: Carrier-Mediated Transport of Peptides and Peptide Analogs, Third International Conference on Drug Absorption, Edinburgh, Scotland, September 28-30, 1988.

6. G.D. Leesman, P.J. Sinko, and G.L. Amidon, The Utility of a Micro-Mixing Model to

approximate a dispersed plug flow model in order to describe gastrointestinal transit and resultant fraction dose absorbed for drugs with nonlinear kinetics, Pharmaceutical Research, 5 (suppl), S-101 (1988), Orlando, FL.

7. P.J. Sinko, G.D. Leesman, and G.L. Amidon, Predicting Fraction Dose Absorbed In Humans

I. Theoretical Analysis, Pharmaceutical Research, 5 (suppl), S-102 (1988), Orlando, FL. 8. P.J. Sinko, G.D. Leesman, and G.L. Amidon, Predicting Fraction Dose Absorbed In Humans

II. Application to Passively and Nonpassively Absorbed Drugs, Pharmaceutical Research, 5 (suppl), S-103 (1988), Orlando, FL.

9. P.J. Sinko, G.D. Leesman, and G.L. Amidon, Theoretical Approach For Predicting Fraction


Dose Absorbed in Humans: Nonlinear Absorption and Stability Considerations, Pharmaceutical Research, 6 (suppl), S-89 (1989), Atlanta, GA.

10. Doo-Man Oh, P.J. Sinko, and G.L. Amidon, Characterization of the Oral Absorption of Some

Penicillins: Determination of Intrinsic Membrane Absorption Parameters in the Rat Small Intestine In Situ, Pharmaceutical Research, 6 (suppl), S-91 (1989), Atlanta, GA.

11. P.J. Sinko, G.D. Leesman and G.L. Amidon. Estimating the Extent of Absorption For

Nonpassively Absorbed Compounds Using A Macroscopic Mass Balance Approach: Stochastic Variability in Small Intestinal Transit Time. Third Symposium: Frontiers of Pharmacokinetics and Pharmacodynamics, April 2-4, 1990, Baltimore, MD.

12. Doo-Man Oh, P.J. Sinko and G.L. Amidon, Peptide transport of β-lactam antibiotics:

structural requirements for an α-amino group, Pharmaceutical Research, 7 (suppl): S-119 (1990) Las Vegas, NV.

13. P.J. Sinko, T.S. Chen and G.L. Amidon. Characterization of fasting chymotrypsin levels in

duodenally fistulated dogs as a function of gastric motility phase, Pharmaceutical Research, 7 (suppl): S-118 (1990) Las Vegas, NV.

14. P.J. Sinko, G.D. Leesman and G.L. Amidon. Determining the effect of stochastic parameter

variability on estimates of the extent of oral drug absorption in humans, Pharmaceutical Research, 7 (suppl): S-132 (1990) Las Vegas, NV.

15. D-M. Oh, P.J. Sinko and G.L. Amidon. Effect of drug-drug interaction on the extent and rate

of oral absorption of carrier-mediated compounds in humans. Pharmaceutical Research, 8 (suppl): S-220 (1991) Washington, DC

16. P.J. Sinko, G.D. Leesman and G.L. Amidon. Predicting oral drug absorption and intestinal

metabolism: Theory and application to peptides and peptide analogs. Pharmaceutical Research, 8 (suppl): S-256 (1991) Washington, DC.

17. P.J. Sinko, G.D. Leesman and J.H. Kou. Determining intrinsic membrane transport

parameters from the perfused intestine experiment using a numerical aqueous resistance, Pharmaceutical Research, 9 (suppl): S-172 (1992) San Antonio, TX.

18. J.P. Gilligan, L. Tyburski, E. Wagner, D.P. Driscoll, V.H. Burkett, D.E. Matthews, P.J.

Sinko, C.A. Smith and W. Stern. A pharmacokinetic and pharmacodynamic comparison of chemically synthesized and recombinant salmon calcitonin, Journal of Bone and Mineral Research 10 (suppl 1): S-261 (1993) Tampa, FL.

19. N.R. Patel, P. Hu and P.J. Sinko. "Site-Specific absorption of anti-AIDS Drugs. I:

Didanosine" Pharmaceutical Research, 10 (suppl): S-214 (1993) Orlando, FL. 20. N.R. Patel, P. Hu and P.J. Sinko. Characterization of the oral absorption mechanism of

didanosine using in vitro and in situ methods, Pharmaceutical Research, 10 (suppl): S-214 (1993) Orlando, FL.

21. P.J. Sinko. Modeling site-specific and discontinuous oral absorption using mass balance


approaches, Pharmaceutical Research, 10 (suppl): S-214 (1993) Orlando, FL. 22. P.J. Sinko, P. Hu, E. Wagner, A. Sturmer, JP. Gilligan and W. Stern. Determination of the

intestinal permeability of recombinant salmon calcitonin, Pharmaceutical Research, 10 (suppl): S-293 (1993) Orlando, FL.

23. J.P. Gilligan, C.L. Smith, L. Tyburski, E. Wagner, W. Stern and P.J. Sinko.

Pharmacokinetics and Pharmacodynamics of recombinant salmon calcitonin after intraduodenal, intravenous and subcutaneous administration in rats, Pharmaceutical Research, 10 (suppl): S-383 (1993) Orlando, FL.

24. P.J. Sinko, C.L. Smith, P. Hu, E. Wagner, L. Tyburski, J.P. Gilligan and W. Stern.

Pharmacokinetics, pharmacodynamics and absolute oral bioavailability of recombinant salmon calcitonin in dogs, Pharmaceutical Research, 10 (suppl): S-384 (1993) Orlando, FL.

25. P.J. Sinko, P. Hu, N.R. Patel and K.R. Pandya, Controlled oral drug delivery: Mechanisms

and modulation of regional intestinal permeability, in: R.H. Guy and J.-P. Marty, editors, Proceedings of the 21st International Symposium on Controlled Release of Bioactive Materials, Controlled Release Society, Inc., Lincolnshire, IL, pp.17-18, 1994 Nice, France.

26. H. Yu, F. Jiang and P.J. Sinko. In vitro methods for assessing intestinal membrane

permeability: comparison to single pass intestinal perfusion, Pharmaceutical Research, 11: S-221 (1994) San Diego, CA.

27. P. Hu, C.E. Frost and P.J. Sinko. Intestinal transport and metabolism of zidovudine in the rat,

Pharmaceutical Research, 11: S-254 (1994) San Diego, CA. 28. A.P. Waclawski and P.J. Sinko. Carrier-mediated intestinal transport of stavudine (d4T) in

rats, Pharmaceutical Research, 11: S-253 (1994) San Diego, CA. 29. P. Hu, A.P. Waclawski and P.J. Sinko. Uptake of didanosine and furosemide into rabbit

intestinal brush border membrane vesicles, Pharmaceutical Research, 11: S-253 (1994) San Diego, CA.

30. D.A. Norris and P.J. Sinko. Characterization of modified diffusion chamber system for

investigating transport across gastrointestinal (GI) mucin, Pharmaceutical Research, 11: S-254 (1994) San Diego, CA.

31. J.P. Gilligan, L.T. McWhorter, V. Burkett-Pazel, P.J. Sinko and W. Stern. "Rapid detection

and identification of salmon calcitonin in plasma after oral and gastrointestinal administration of recombinant salmon calcitonin, Pharmaceutical Research, 11: S-19 (1994) San Diego, CA.

32. C.L. Smith, J.P. Sutyak, W. Stern, J.P. Gilligan and P.J. Sinko. Regional intestinal

absorption of recombinant salmon calcitonin in the Intestinal-Vascular Access Port (IVAP) dog model, Pharmaceutical Research, 11: S-383 (1994) San Diego, CA.

33. H. Yu, F. Jiang, W. Stern and P.J. Sinko, Intestinal binding and degradation of recombinant

salmon calcitonin, Pharmaceutical Research, 11: S-254 (1994) San Diego, CA.

Patrick J. Sinko, page 37 34. E. Wagner, H. Yu, L.T. McWhorter, J.P. Gilligan, P.J. Sinko and W. Stern, Metabolism of

Recombinant Salmon Calcitonin By Intestinal Segments from Rat Duodenum, Ileum and Colon, Pharmaceutical Research, 11: S-408 (1994) San Diego, CA.

35. J.P. Gilligan, C.L. Smith, L.T. McWhorter, E. Wagner, P.J. Sinko and W. Stern, Enhanced

Bioavailability of Recombinant Salmon Calcitonin in Rats: Regional Intestinal Administration with Protease Inhibitors, Pharmaceutical Research, 11: S-409 (1994) San Diego, CA.

36. A.P. Waclawaski and P.J. Sinko, Metabolism of Stavudine (d4T) and Thymidine in Rat

Intestinal Homogenates, Pharmaceutical Research, 12 (suppl): S- 385 (1995), Miami Beach, FL.

37. A.P. Waclawaski, P.V. Balimane, and P.J. Sinko, Quantitation of the in situ intestinal

anabolism of zidovudine (AZT) in rat, Pharmaceutical Research, 12 (suppl): S-384 (1995), Miami Beach, FL.

38. P.J. Sinko, C.L. Smith, J.P. Sutyak, and G.D. Leesman, Regional intestinal bioavailability of

didanosine in an in vivo intestinal-vascular access port (IVAP) dog model, Pharmaceutical Research, 12 (suppl): S-426 (1995), Miami Beach, FL.

39. P. Hu and P.J. Sinko, Carrier-mediated intestinal transport of AZT in rabbit brush border

membrane vesicles, Pharmaceutical Research, 12 (suppl): S-304 (1995), Miami Beach, FL. 40. P.J. Sinko, G.D. Leesman, J. Nedelman, H.F. Schran and D.G. Pope, Establishing oral

controlled-release specifications using pharmacokinetic simulations: Application to Dynacirc CR, Pharmaceutical Research, 12 (suppl): S-398 (1995), Miami Beach, FL.

41. P.J. Sinko, A.P. Waclawaski, H. Yu and G.D. Leesman, Use of the NAR-NLR analysis for

quantifying the transport of compounds with high intestinal permeability, Pharmaceutical Research, 12 (suppl): S-311 (1995), Miami Beach, FL.

42. F. Delie, D.A. Norris, P.J. Sinko, and W.E. Rubas, CACO-2 cells as an in vitro model for the

intestinal uptake of microparticulates, Pharmaceutical Research, 12 (suppl): S-234 (1995), Miami Beach, FL.

43. D.A. Norris, M.E. Labib, F. Delie, W.E. Rubas, and P.J. Sinko, The uptake and translocation

of microparticles through GI mucin, Pharmaceutical Research, 12 (suppl): S-233 (1995), Miami Beach, FL.

44. H. Yu, T.J. Cook, and P.J. Sinko, Comparison of the ileal permeability of several compounds

in human, rabbit and rat tissue, Pharmaceutical Research, 12 (suppl): S-304 (1995), Miami Beach, FL.

45. H. Yu, G.M. Grass, and P.J. Sinko, A comparison of the properties of Caco-2 cells grown on

polyester and polycarbonate membranes, Pharmaceutical Research, 12 (suppl): S-304 (1995), Miami Beach, FL.

Patrick J. Sinko, page 38 46. A.P. Waclawski and P.J. Sinko, Characterization of stavudine uptake by rabbit intestinal

brush border membrane vesicles (BBMV), Pharmaceutical Research, 12 (suppl): S-352 (1995), Miami Beach, FL.

47. W. Stern, E. Wagner, L.M. Falzone, L.T. McWhorter, D. Charles, P.J. Sinko, B. Perry, V.

Makhey, and J.P. Gilligan. Enhanced Oral and Intestinal Bioavailability of Recombinant Salmon Calcitonin Journal of Bone and Mineral Research (1996) Seattle, WA.

48. H. Yu, T.J. Cook, and P.J. Sinko. Reduced Carrier-Mediated Transport By Caco-2 Cell

Monolayers at High Passage Numbers, Pharmaceutical Research, 13 (suppl): S-242, 1996. 49. T.J. Cook, H. Yu, and P.J. Sinko. The C2BBe Cell Line: A Stable Brush-Border Expressing

Caco-2 Clone, Pharmaceutical Research, 13 (suppl): S-241, 1996. 50. P. Hu and P.J. Sinko. Carrier-Mediated Transport of Zidovudine in Rabbit Basolateral

Intestinal Membrane Vesicles (BLMV), Pharmaceutical Research, 13 (suppl): S-247, 1996. 51. V. Makhey and P.J. Sinko. Mechanism of Action, Regional Dependence, and Molecular

Weight/Size Selectivity of Intestinal Permeation Enhancers, Pharmaceutical Research, 13 (suppl): S-248, 1996.

52. P.V. Balimane and P.J. Sinko. Carrier-Mediated Intestinal Transport of 3'-Deoxy 3'-

Fluorothymidine (FLT) in Rats, Pharmaceutical Research, 13 (suppl): S-247, 1996. 53. P.V. Balimane, A.P. Waclawski, and P.J. Sinko. A Model for Estimating the Bioavailability

Variability of Anti-HIV Nucleoside Analogues: Impact of Absorption Mechanism, Pharmaceutical Research, 13 (suppl): S-359, 1996.

54. P.J. Sinko, A.P.Waclawski, P.V. Balimane, and Z.N. Mahmoudi. Quantitative Evaluation of

the Effect of Fluid Uptake on the Intestinal Permeation of Thymidine Analogues. Convective and Concentrative Effects, Pharmaceutical Research, 13 (suppl): S-245, 1996.

55. H. Yu and P.J. Sinko. Delineation of the Resistances of the Filter, Aqueous Boundary Layer,

and Monolayer Using Caco-2 Cells Cultured on Polycarbonate and Polyester Microporous Filters, Pharmaceutical Research, 13 (suppl): S-357, 1996.

56. T.J. Cook, Y. Jiansheng, and P.J. Sinko. Involvement of the organic cation and oligopeptide

carrier proteins in the apical transporter of vacyclovir across Caco-2 cell monolayers, Pharmaceutical Research, 14 (suppl): S-20, 1997.

57. H. Yu, R.L. Oberle, T.F. Jones, and P.J. Sinko. Caco-2 cell line as an in vitro system for

cytotoxicity evaluation of pharmaceutical excipients, Pharmaceutical Research, 14 (suppl): S-27, 1997.

58. P. Hu, And P.J. Sinko. Carrier-mediated intestinal absorption of valacyclovir, the L valyl

ester prodrug of acyclovir. Involvement of multiple apical membrane transporters in rabbits, Pharmaceutical Research, 14 (suppl): S-29, 1997.

59. P.V. Balimane, V. Makhey, and P.J. Sinko. Study of the transport characteristics of a novel


thiocarboxanilide pentenyloxy ether derivative UC-781: an inhibitor of human immunodificiency virus type-I replication, Pharmaceutical Research, 14 (suppl): S-31, 1997.

60. D.A. Norris and P.J. Sinko. The role of surface hydrophobicity in the transport of polystyrene

microspheres through Caco-2 cell monolayers and intestinal mucin, Pharmaceutical Research, 14 (suppl): S-58, 1997.

61. D.A. Norris, N. Puri, P.J. Sinko. The use of thin layer wicking as a technique to determine

absolute surface hydrophobicity of intact microspheres, Pharmaceutical Research, 14 (suppl): S-58, 1997.

62. N. Puri, P.J. Sinko. Enhanced adjuvancy of muramyl dipeptide (MDP) by controlling the

surface bulk properties of vaccine delivery vehicles, Pharmaceutical Research, 14 (suppl): S-58, 1997.

63. H. Yu, T.F. Jones, R.L. Oberle, and P.J. Sinko. Evaluation of pharmaceutical excipients for

improving solubility and oral absorption of insoluble drugs using the Caco-2 cell line, Pharmaceutical Research, 14 (suppl): S-253, 1997.

64. V.D. Makhey, and P.J. Sinko. Investigation of stability, cytochromes P450-mediated

metabolism and MDR-mediated efflux of the HIV protease inhibitor, saquinavir in humans and rats, Pharmaceutical Research, 14 (suppl): S-525, 1997.

65. Y. Jiansheng, V.D. Makhey, W. Stern, J.P. Gilligan, and P.J. Sinko. Effect of pH on

recovery of intestinal tissue after exposure to permeation enhancers, Pharmaceutical Research, 14 (suppl): S-645, 1997.

66. V.D. Makhey, and P.J. Sinko. Regional functional expression of multidrug resistance efflux

pumps, Pgp and MRP, in human and rat intestines, Pharmaceutical Research, 14 (suppl): S-646, 1997.

67. P.V. Balimane, and P.J. Sinko. Determination of mechanism of absorption of valacyclovir

(VACV), the L-valyl ester prodrug of acyclovir (ACV) in rats, Pharmaceutical Research, 14 (suppl): S-649, 1997.

68. B.A. Perry, J.P. Sutyak, W. Stern, and P.J. Sinko. Impact of intestinal dilution and spreading

on effectiveness of pharmaceutical excipients: investigation regional differences in pH recovery and bowel motility in dogs fitted with intestinal and vascular access ports, Pharmaceutical Research, 14 (suppl): S-653, 1997.

69. B.A. Perry, J.P. Sutyak, W. Stern, and P.J. Sinko. Maximizing longevity of the intestinal and

vascular access port canine model for investigating regional dependency of drug delivery, Pharmaceutical Research, 14 (suppl): S-563, 1997.

70. D.A. Norris, A. Guo, V. D. Makhey, and P.J. Sinko. Functional expression and

immunoquantitation of multidrug resistance (MDR) efflux pumps, Pgp and MRP, in Caco-2 cells as a function of passage number, Pharmaceutical Research, 14 (suppl): S-669, 1997.

71. S. Ramanathan, P.J. Sinko. The Intestinal Transport of Camotothecin, A Highly Lipophilic


Drug, Across Caco-2 Cells is Apparently Mediated by Specialized Tranport Mechanisms, PharmSci Supplement, 1:1, S-11, 1998.

72. Guo A., P. Hu, P.J. Sinko. Interactions of a Non-peptidic Drug, Valacyclovia, the L-Valyl

Ester of Acyclovir, with Human Intestinal Peptide Transporter, PharmSci Supplement, 1:1, S-388, 1998.

73. N. Puri, and P. J. Sinko. Adjuvancy Enhancement Through Modulation of the Surface and

Bulk Properties of Ovalbumin Microspheres, PharmSci Supplement, 1:1, S-201, 1998. 74. N. Puri, E. H. Weyand, H. Yacowitz, and P. J. Sinko. Parenteral Immunization Route As A

Determinig Factor in Modulating the Microparticle Mediated Immune Response In Vaccine Therapy, PharmSci Supplement, 1:1, S-291, 1998.

75. P. V. Balimane, I. Tamai, F. H. Leibach, A. Tsuji, and P. J. Sinko. Valacyclovir: A Non-

typical Substrate for Human Intestinal Peptide Transporter hPepT1, PharmSci Supplement, 1:1, S-650, 1998.

76. G. C. Williams, J. R. Kunta, and P. J. Sinko. Characterization of the Secretory Efflux of

Ritonvir, An HIV Protease Inhibitor, Using Rat Jejunum, PharmSci Supplement, 1:1, S-12, 1998.

77. J. Kunta, G. C. Williams, and P. J. Sinko. Investigation of Regional Intestinal Efflux of an

HIV Protease Inhibitor, Saquinavir, in Rat Jejunum, PharmSci Supplement, 1:1, S-457, 1998. 78. D. Norris and P. J. Sinko. The Effect of Surface Hydrophobicity on Microparticle (MP)-

Mucin and MP-Caco-2 Cell Interactions, PharmSci Supplement, 1:1, S-122, 1998. 79. B.A. Perry, J.P. Sutyak, W. Stern, and P. J. Sinko. Impact of Intestinal Dilution and

Spreading on Effectiveness of Pharmaceutical Excipients: Investigation of Regional Differences in Capsule Dissolution, pH Recovery and Bowel Motility in Beagle Dogs, PharmSci Supplement, 1:1, S-457, 1998.

80. Daniel Norris, Navneet Puri, Mohamad E. Labib and P. J. Sinko. Determining the Absolute

Surface Hydrophobicity of Microparicles Using Thin Layer Wicking, Controlled Release Society, 59:2, 1999 173-185.

81. Srinivasan Ramanathan and P. J. Sinko. The Investigation of the Transport Properties of Tat-

Peptide Inhibitor Congugated to Poly (Ethyel) Glycol based biopolymoric Delivery Systems, Controlled Release Society, 26,1999 5201.

82. Daniel Norris and P. J. Sinko. The Role of Surface Hydrophobicity in the transport of

polystrene microshpere through Caco-2 Cell Monolayer and Intestinal Mucin, Controlled Release Society, 26,1999.

83. N. Puri and P. J. Sinko. Physicochemically modified ovalbumin microspheres mediated

adjuvancy enhancement of muramyl dipeptide, Proceed. Int=l Symp. Control. Rel. Bioact. Mater., Controlled Release Society, Inc., 26,1999.

Patrick J. Sinko, page 41 84. Rozett. K, Lonardo, E.C., Weyand, E.H. and P. J. Sinko. Studies of the Intestinal

Permeabilities of Hydrocarbons in the Rat, Society of Toxiology Annual Meeting, The Toxicologist, 38:54, 1999.

85. Srinivasan Ramanathan and P. J. Sinko. Transport Characteristics of A Tat-Inhibitor

Conjugated to a Peg Based Delivery System Across Caco-2 Cells, PharmSci Supplement 1-1 S-2863, 1999.

86. Jeevan Kunta and P. J. Sinko. Characterization of Efflux Kinetics of Etoposide in Rabbit

Small Intestine and Colon, PharmSci Supplement, 1-1 S-2817, 1999. 87. Pankaj Paranjpe, Praveen Balimane and P. J. Sinko. Structure-Uptake Relationships of

HPEPT1: Uptake of Valacyclovir in Transiently Transfected Hela Cells, PharmSci Supplement, 1-1 S-1451 1999.

88. Pankaj Paranjpe and P. J. Sinko. Charcterization of the Intestinal Transport Mechanism of

Toptecan Across Cacp-2 Cells, PharmSci Supplement, 1-1 S-2910, 1999. 89. Roger (Feng) Luo and P. J. Sinko. Intestinal Efflux of Camptothecins is Likely to be

Mediated by Efflux Transporter PGP and CMOAT, PharmSci Supplement, 1-1 S-2915, 1999. 90. Roger (Feng) Luo and P. J. Sinko. Comparison of the Absorptive and Efflux Kinetics of

Camptothecin and its Analogues Irinotecan and Topotecan Across Caco-2 Cells, PharmSci Supplement, 1-1 S- 2126, 1999.

91. Yong Hee Lee, Jeevan Kunta and P. J. Sinko. Differentiation of Gut and Hepatic First-Pass

Effect of Drugs: 1. Studies of Verapamil in IVAP dogs, PharmSci Supplement, 1-1 S-2695, 1999.

92. Roger (Feng) Luo and P. J. Sinko. Determination of the mechanisms of Transport of

Camtothecin Across MDCK Cells Overexpressing MDR1, MDRP1, and cMOAT PharmSci Supplement, 1-1 S-2134 1999.

93. Jeevan Kunta and P. J. Sinko. Delineating Drugs Efflux Pathways in Multidrug Resistance

Cell Lines for a Model Drug, Etoposide, PharmSci Supplement, 1-1 S-1510, 1999. 94. Gregory Williams and P. J. Sinko. Characterization of Saquinavir Transport Using MDCKII

Cell Monolayers Over Expressing P-glcoprotein, MRP and CMOAT (MRP2), PharmSci Supplement, 1-1 S-2932 1999.

95. S. Ramanathan, S. Stein, P. Prasad, F.H. Leibach and P. J. Sinko. Increasing the Transport of

a 9-Amino Acid Tat-Inhibitor Using a Poly(Ethylene Glycol) Biopolymer Targetting the Sodium Dependent Mulytivitamin Transporter, Controlled Release of Bioactive Materials, 219-220, 2000.

96. Gregory Williams, Jeevan Kunta, Ailan Guo and Patrick J, Sinko. Characterization of

Saquinavir Transport Using MDCKII Cell Monolayers Over Expressing P-gylcoprotein, MRP and cMOAT (MRP2), Millenial Congress Supplement, 2-3076, 2000.

Patrick J. Sinko, page 42 97. Srinivasan Ramanathan, Stanley Stein and Patrick J. Sinko. Transport of a Novel Anti-Aids

Agent Using a PEG Based Biopolymeric System Across Caco-2 Cells. Millennial World Congress Supplement, 1-2008, 2000.

98. G. C. Williams, A. Liu, A. Guo, P. J. Sinko, Direct Evidence that Saquinavir is a Substrate

for MRP (MRP1) and cMOAT (MRP2), PharmSci Supplement, 2: 2172 2000. 99. J. R. Kunta, B. A. Perry, P. J. Sinko, A Novel Intestinal and Vascular Access Port (IVAP)

Rabbit Model to Study the Regio-Specific Oral Absorption and First Pass Elimination of Drugs, PharmSci Supplement, 2: 2166, 2000

100. R. S. Geary, L. Truong, S. Weinbach, C. Teng, L. G. Tillman, B. A. Perry, P. J. Sinko, G. E.

Hardee, Intestinal Site of Absorption and Tolerability of Formulated 2'-O-methoxyethyl (MOE) Modified Antisense Oligonucleotide in a Conscious Dog Model, PharmSci Supplement, 2: 3294 2000.

101. C. Sage, N. Johnson, Y. Lee, R. Christopher, P. Gordon, T. Hollenbeck, B. Phan, P. J. Sinko, A. Hillyard, G. Grass, In Silico Prediction of Caco-2 Permeability from Molecular Structure, PharmSci Supplement, 2: 2180 2000.

102. X. Zhang, P. Hu, P. J. Sinko, Mediation of Camptothecin (CPT) Intestinal Absorption by a

Bile Acid Transporter is suggested by a Rabbit Small Intestine Brush Border Membrane Vesicle (BBMV) Study, PharmSci Supplement, 2000.

103. F. R. Luo, P. V. Paranjpe, E. Rubin, P. J. Sinko, In Vitro and In Vivo Correlation (IVIVC) of Caco-2 Cell Permeability and Absorption Rate in Human Subjects for Orally Administered Camptothecin (CPT), PharmSci Supplement, 2: 3267 2000.

104. S. Park, H. Lee, P. J. Sinko, Use of In Vitro Brain Microvessel Endothelial Cell (BMEC)

Culture for Characterizing Biotin Uptake and Transport, PharmSci Supplement, 2: 3265 2000.

105. S. Ramanathan, P. Prasad, S. Stein, P. J. Sinko, The Carrier Mediated Transport of a Biotin

Modified PEG across Caco-2 Cell Monolayers, PharmSci Supplement, 2: 2015, 3263 2000. 106. J. Yang, P. Sinko, V. Lee, Transport of an Amino Acid Ester Prodrug, L-Valacyclovir, in

Rabbit Conjunctival Epithelial Cells, PharmSci Supplement, 2: 4127 2000. 107. D. Norris, R. Retajczyk, P. Sinko, G. Leesman, J. Trout, Methods and Metrics for the

Comprehensive Comparison of Absorption versus Time Curves, PharmSci Supplement, 2: 3535 2000.

108. P. J. Sinko, Acquiring and Applying Screens of ADME Properties to the Selection of Drug

Candidates, PharmSci Supplement, 2: 2000. 109. G. Timony, D. Norris, G. Leesman, R. Retajczyk, S. Tran, Y. Chen, Y. Lee, N. Johnson, J.

Castelo, K. Lee, R. Christopher, P. Sinko, G. Grass, Development and Validation of the Physiologically Based IDEA Predictive Model, PharmSci Supplement, 2: 3523 2000.

Patrick J. Sinko, page 43 110. G. Leesman, D. Norris, G. Timony, Y. Chen, W. Pirson, F. P. Theil, A. H. Schmitt-Hoffman,

Y. H. Lee, J. Doerr-Stevens, P. Gordon, R. Retajczyk, S. Tran, N. Johnson, J. Castelo, R. Christopher, G. Grass, P. Sinko, Assessment of the Physiologically-Based IDEATM Predictive Model Using an External (Blinded) Data Set, PharmSci Supplement, 2: 3512 2000.

111. Y. H. Lee, N. Johnson, K. J. Lee, J. Castelo, K. Click, P. Gordon, T. Hollenbeck, B. Phan, R.

J. Christopher, G. Grass, P. J. Sinko, Utility of a 24-Well Format of Caco-2 Monolayer for Absorption Screening and Prediction, PharmSci Supplement, 2: 2196 2000.

112. Guo A., G. T. Knipp, P. J. Sinko, Characterization of mdr1, MRP1 and cMOAT Gene

Expression in Human and Rat Intestine, PharmSci Supplement, 2: 4166 2000. 113. K. J. Lee, Y. H. Lee, N. Johnson, J. Castelo, K. Click, P. Gordon, T. Hollenbeck, B. Phan, R.

J. Christopher, G. Grass, P. J. Sinko, Comparison of the Permeability Characteristics of BCS Compounds in Various Intestinal Regions of Rabbit and Caco-2 Models, PharmSci Supplement, 2: 2194 2000.

114. S. Park, S. Stein, and P.J. Sinko, Targeting the sodium Dependent Multivitamin Trasporter

(SMVT) in the Blood-Brain Barrier (BBB) to Increase the Transport of Biotin Conjugated Peptides and Polymers, Controlled Release Society, 243-244, 2001.

115. S. Ramanathan, S. Stein, M. Leibowitz and P. J. Sinko, Targeting the Intestinal Biotin

Transporter to Enhance the Permeability of Peptides and Their Biopolymeric Conjugates, Controlled Release Society, 993-994, 2001.

116. B. Qiu, S. Stefanow, M. Leibowitz, P. Sinko and S. Stein, A Novel Injectable Polymer

Hydrogel System-Depogel for Controlled Delivery of Small and Large Molecule Drugs, Controlled Release Society, 1009-1010, 2001.

117. Seong-Hee Park, Barbara A. Perry and Patrick J. Sinko. Targeting the Sodium Dependent

Multivitamin Transporter (SMVT) in the Blood-Brain Barrier to Increase the In Vitro and In Vivo Transport of Biotin Conjugated Polymers as Bioreversible Drug Carriers, PharmSci Supplement, 3: T3283, 2001.

118. Hee-Sang Lee,Yung-Seop Lee, and Patrick J. Sinko, Decision Tree-Based Method for

Predicting the Brain Partitioning of Drugs, PharmSci Supplement, 3: T3740, 2001. 119. Hee-Sang Lee and Patrick J. Sinko, An Improved Barrier Function of In Vitro Blood-Brain

Barrier Model: with 3.0 um Pore Size Polycarbonate Membrane Inserts,PharmSci Supplement, 3:T3407, 2001.

120. P. V. Paranjpe,A. Liu, E. Rubin, and P. J. Sinko, Investigating the Secretory Transport

Mechanism of Topotecan, PharmSci Supplemen,t 3: R5225, 2001. 121. J. R. Kunta, B.A. Perry, I. Segarra, O. Timofeev and P. J. Sinko, Modulation of the Oral

Absorption of Saquinavir in an Intestinal and Vascular Access Ported (IVAP) Rabbit Model Using Ritonavir, Midazolam and Cyclosporine A., PharmSci Supplement, 3:R5110, 2001.

Patrick J. Sinko, page 44 122. P. Chao and P.J. Sinko, Comparison of Drug Efflux Transporters Expression in Human and

Rat Lung cell Lines, Rat Lung, and Rat Lung Cell Cultures, PharmSci Supplement, 3: T3714, 2001.

123. Gregory C. Williams and Patrick J. Sinko. Saquinavir Transport Through MDCKII Cell

Monolayers Overexpressing P-Glycoprotein Depends on Seeding Density and Substrate, PharmSci Supplement, 3: T3378, 2001.

124. Xiaoping Zhang and Patrick J. Sinko. Appending a Biotin to 10 kDa Polyethylene Glycol

(PEG) Changes the Intestinal Absorptive Transport Mechanism, PharmSci Supplement, 3: W4232, 2001.

125. Ailan Guo and Patrick J. Sinko. Expression Patterns of Cytochrome P-450 3A4 and PXR

in the Human Gastrointestinal tract and CYP3A4 Induction by HIV Protease Inhibitors and Anticancer Drugs in Caco-2 Cells, PharmSci Supplement, 3: T3346, 2001.

126. Srinivasan Ramanathan, Guobao Zhang, Stanley Stein and P. J. Sinko. Interactions of

Linear and Branch Biotin-PEGs with the Intestinal Biotin Transporter, PharmSci Supplement, 3: W4074, 2001.

127. Bo Qiu, M. Leibowitz, S. Stein and P. J. Sinko, In Situ Forming Polymer Hydrogel for

Sustained Drug Delivery, PharmSci Supplement, 3: W4750b, 2001. 128. Gregg A. Timony, Lelania Taylor-Mora, Glen Leesman, Shawn Tran, Daniel Norris,and

P.J. Sinko “A Novel Input Function and Compartmental Model Describes Absorption for a Diverse Group of Compounds”, PharmSci Supplement, 3: T3789, 2001.

129. Oleg Timofeev, Helen Usansky, Zhe-Ming Gu, Ignacio Segarra, Howard Sands, Thomas

J. Cook, and Patrick J. Sinko, LC/MS/MS Quantification of 9-Nitrocamptothecin and 9-Aminocamptothecin in Dog Plasma Using Atmospheric Pressure Chemical Ionization or Electrospray Ionization Methods, PharmSci Supplement, 3: W4705, 2001.

130. Daniel A. Norris, Ellen Okamoto, Rachel Retajczyk, Glen D. Leesman, Gregg Timony

and Patrick J. Sinko, “The Importance of Absorption Rate in Prediction of First Pass Metabolism”, PharmSci Supplement, 3: T3788, 2001.

131. Yong Hee Lee, Kyoung-Jin Lee, Nikole Johnson, Jesus Castelo, Karen Click, Ronald

Christopher, Perry Gordon, Tom Hollenbeck, Deirdre Moylan, Virgilio Ereso, Kevin Holme, George Grass, Patick J. Sinko, Impact of Experimental Conditions on In Vitro Permeability: (1) Correlations in Inter-Laboratory Caco-2", PharmSci Supplement, 3: T3251, 2001.

132. Nikole Johnson, Kyoung-Jin Lee, Jesus Castelo, Karen Click, Ronald Christopher, Perry

Gordon, Tom Hollenbeck, Deirdre Moylan, Virgilio Ereso, Kevin Holme, George Grass, Yong Hee Lee, and Patick J. Sinko, Impact of Experimental Conditions on In Vitro Permeability: (2) Effect of pH, Buffer, and CO2 Incubation in Caco-2", PharmSci Supplement, 3: T3262, 2001.

133. Tamara Minko, Patrick J. Sinko, Stanley Stein, Sonia S. Dharap, Bo Qiu, Anthony T.

Fabbricatore, Yang Wang, Molecular Targeting of Drug Delivery Systems to Ovarian


Cancer by BH3 and LHRH peptides, International Symposium on Tumor Targeted Delivery Systems, The National Cancer Institute and Controlled Release Society, 5:6-9, Rockville MD, September 22-25, 2002.

134. Anita K Lalloo, Jianglin Ma, Stanley S Stein, Patrick J Sinko, In Vitro Characterization Of

A Novel In Situ Forming Hydrogel For Controlled Delivery Of The Camptothecins, PharmSci Supplement, T3341, 2002.

135. S. Park, J. E. Fitzgibbon, S. Pooyan, S. Stein, and P. J. Sinko, Preparation and evaluation

of novel anti-HIV-1 bioconjugates, PharmSci Supplement, W5262, 2002 136. Piyun Chao and Patrick J. Sinko, Passive Pulmonary Targeting and Tissue Distribution of

Microspheres, PharmSci Supplement, W4157, 2002. 137. Helen H. Usansky and Patrick J. Sinko, Quantitative Prediction of LogBB Values for

Compounds Transported Through Carrier-Mediated Mechanisms Using in vitro Permeability Data from Brain Microvessel Endothelial Cell (BMEC) Monolayers, PharmSci Supplement, M1228, 2002.

138. Sung-Hack Lee, Jeevan R. Kunta, Helen H. Usansky, and Patrick J. Sinko, Studies of verapamil in Intestinal and Vascular Access Ported (IVAP) Rabbits, PharmSci Supplement, T2246, 2002.

139. Xiaoping Zhang, Shahriar Pooyan, and Patrick Sinko, Evaluation Of The Potential In

Drug Delivery Of A Cell Penetrating Peptide, R.I.-Tat-9 Enhances Uptake Of A Linear Poly (Ethylene Glycol) 3400 (PEG) Into Caco-2 Cells, But Not Transport, PharmSci Supplement, R6106, 2002.

140. Pankaj V. Paranjpe, Tamara Minko, Bo Qiu, Anita Lalloo, Roney Won, Stanley Stein,

Patrick Sinko, Enhancing The Anticancer Efficacy Of Camptothecin Using Poly (Ethyleneglycol) Conjugates In Human Ovarian Carcinoma Cells, PharmSci Supplement, R6109, 2002.

141. Yaming Su, Sung-Hack Lee, Gregory C. Williams, Kurt Amsler and Patrick J. Sinko,

Evidence for a MK571 Sensitive Basolateral to Apical Transport Mechanism Having Basolateral Localization, PharmSci Supplement R6173, 2002.

142. S. H. Lee, Y. Su, G. C. Williams, A. Liu, G. T. Knipp, A. Guo, K. Amsler and P. J. Sinko,

The Roles Of Multiple Transporters In The Intestinal Absorption Of Saquinavir, PharmSci Supplement, W5057, 2002.

143. Barbara Perry, Ignacio Segarra, Oleg Timofeev, John Sutyak , Howard Sands , Thomas J.

Cook and Patrick J. Sinko, The low oral bioavailability of 9-Nitrocamptothecin (9-NC) in a beagle dog model with a permanent portal vein sampling port is primarily due to extensive intestinal metabolism to 9-Aminocamptothecin (9-AC), PharmSci Supplement, T2200, 2002.

144. Barbara Perry, Alan Higgins, Nathaniel Holmes, and Patrick J. Sinko, Effects of Gastric

pH and Emptying on Effectiveness of Liquid HIM2 Insulin Formulations in Conscious


IVAP Beagle Dogs, PharmSci Supplement, T2190, 2002. 145. Tamara Minko, Patrick J. Sinko, Thomas J. Cook, Stanley Stein, Targeted Proapoptotic

Drug Delivery systems in Cancer Chemotherapy”, International Journal of Molecular Medicine Volume 10, Supplement 1, 2002.

146. Tamara Minko, Patrick J. Sinko, Thomas J. Cook, Stanley Stein, Sonia S. Dharap, Refika

I. Pakunlu, Bo Qiu, Novel Targeted Drug Delivery Systems Combining Anticancer Drug, Targeting Moiety and Suppressors of Multidrug Resistance and Antiapoptotic Cellular Defense, Controlled Release Society, 11th International Symposium on Recent Advances in Drug Delivery Systems, March 6, 2003.

147. Tamara Minko, Patrick J. Sinko, Thomas J. Cook, Stanley Stein, Sonia S. Dharap, Refika

I. Pakunlu, and Bo Qui, Molecular Targeting of Pump and Nonpump Cellular Resistance in Cancer, The 2003 Annual Retreat on Cancer Research in New Jersey, P42, June 11, 2003.

148. Yaming Su, Xiaoping Zhang and Patrick J. Sinko, Organic Anion Transporting

Polypeptides (Oatps), Mrp2 And Pgp Facilitate Saquinavir Transport In Hepg2 Cells, 12th North American International Society for the Study Of Xenobiotics meeting, Drug Metabolism Reviews, 35:2: 71, October 2003.

149. Yaming Su, Xiaoping Zhang and Patrick J. Sinko, Human Organic Anion Transporting

Polypeptides Oatp1 (Slc21a3) And Oatp2 (Slc21a6) Facilitate Saquinavir Transport, 12th North American International Society for the Study Of Xenobiotics meeting, Drug Metabolism Reviews, 35:2: 71, October 2003.

150. Helen H. Usansky and Patrick J. Sinko, Enhanced In Silico Prediction Of Human Oral

Absorption Kinetics Using Caco-2 Permeability Data, 12th North American International Society for the Study Of Xenobiotics meeting, Drug Metabolism Reviews, 35:2: 168, October 2003.

151. Sung-Hack Lee, Jungil Hong, Chung S. Yang and Patrick J. Sinko, In Vitro Inhibition Of

Saquinavir Efflux In Mdckii Cells By Tea Flavonoids, 12th North American ISSX meeting, Metabolism Reviews, 35:2: 154, October 2003.

152. S. Gunaseelan, S. Stein and Patrick J. Sinko, Synthesis of Novel Poly(ethylene

Glycol)(PEG)-And Retro-Inverso(R.I.) CK-Tat9-Based Saquinavir Derivatives, PharmSci supplement, M1096, October 2003.

153. Y. Su, X. Zhang and Patrick J. Sinko, Human Organic Anion Transporting Polypeptides

Oatp1 (SLC21A3) and Oatp2 (SLC21A6) Facilitate Saquinavir Transport, PharmSci supplement, T2154, October 2003.

154. Y. Su, X. Zhang and Patrick J. Sinko, Organic Anion Transporting Polypeptides (OATPS)

Mrp2 and Pgp Facilitate Saquinavir Transport In Hep G2 Cells, PharmSci supplement, T2155, October 2003.

155. S. Park and Patrick J. Sinko, Investigation of the Efflux Transport Mechanism of


Saquinavir Across the Blood Brain Barrier (BBB) Using an In Situ Mice Brain Perfusion Technique, PharmSci supplement, T2164, October 2003.

156. P. Chao, S. Stein and Patrick J. Sinko, Enhanced Passive Pulmonary Targeting and

Retention of Pegylated Microspheres, PharmSci supplement, T3008, October 2003. 157. S. Gunaseelan, O. Debrah, S. Stein and Patrick J. Sinko, Determination of Saquinavir

Concentration and Hydrolysis Rate of Saquinavir-Cysteine Ester Using Protease Inhibition Assay, PharmSci supplement, W4060, October 2003.

158. S. Dharap, B. Qui, S. Stein and Patrick J. Sinko, Molecular Targeting of Proapoptotic

Drug Delivery Systems to Cancer by Bh3 and LHRH Peptides, PharmSci supplement, W5053, October 2003.

159. A.K.Lalloo, S. Stein and Patrick J. Sinko, Controlled Release of Camptothecins from a

novel InSitu-Forming Hydrogel Using a Two Phase System, PharmSci supplement, W5126, October 2003.

160. H. H. Usansky and Patrick J. Sinko, Enhanced In Silico Prediction of Human Oral

Absorption Kinetics Using Caco-2 Permeability Data, PharmSci supplement, R6109, October 2003.

161. P. V. Paranjpe, S. Stein and Patrick J. Sinko, Targeting Intracellular Release of

Camptothecin Bioconjugates to Cancer Cells and Programming the Release Rate Using Amino Acid Linkers, PharmSci supplement, R6139, October 2003.

162. L. Wan and Patrick J. Sinko, PEG-Based Bioconjugates Enhance the InVitro Anti-HIV

Actilvity of a peptidic HIV-1 Tat Anagonist, PharmSci supplement, R6146, October 2003. 163. X. Zhang, L. Wan and Patrick J. Sinko, Cell Type-Specific Internalization of R.I.-TAT-9,

A Cell Penetrating Peptide (CPP), PharmSci supplement, R6152, October 2003. 164. Pankaj V. Paranjpe, Stanley Stein and Patrick J. Sinko, Tumor-Targeted Bioconjugate

Based Delivery of Camptothecin: Programming the Release Rate and Site Using Amino Acid and Peptide Linkers, 31st Annual Meeting and Exposition of the Controlled Release Society, Honolulu, Hawaii, 169, June 2004.

165. Anita K. Lalloo, Piyun Chao, Peidi Hu, Sung-Hack Lee, Stanley Stein, Patrick J. Sinko, In

Vivo Characterization of a Novel Subcutaneous In Situ Forming Hydrogel, 31st Annual Meeting and Exposition of the Controlled Release Society, Honolulu, Hawaii, 207, June 2004.

166. Tamara Minko, Sonia S. Dharap, Simi Gunaseelan, Stanley Stein, Patrick J. Sinko, Refika

I. Pakunlu, Yang Wang, Bo Qui, Targeted Proapoptic Anticancer Drug Delivery System, 31st Annual Meeting and Exposition of the Controlled Release Society, Honolulu, Hawaii, 108, June 2004.

167. Sung-Hack Lee, Jeevan R. Kunta, Barbara A. Perry, and Patrick J. Sinko, Effect of

Ritonavir and Midazolam on the Absorption of Saquinavir in Intestinal and Vascular Access Ported (IVAP) Rabbits, Drug Metabolism Reviews, 83, 2004.

Patrick J. Sinko, page 48 168. Seong Hee Park and Patrick Sinko, Characterization of Biotin Transport across the Blood-

brain barrier in mice and Correlation with In Vitro Data, PharmSci Supplement, T2263, November 2004.

169. Anita K. Lalloo, Piyun Chao, Peidi Hu, Sung-Hack Lee, Tamara Minko, Stanley Stein,

Patrick J. Sinko, Pharmacokinetic And Pharmacodynamic Evaluation Of Topotecan From A Novel Subcutaneously Administered In Situ Forming Hydrogel, PharmSci Supplement, T2150, November 2004.

170. Y. Su, E. Rubin, and P. Sinko, Down-regulation Of Bcrp (abcg2) By Small Interfering

Rna (sirna) Restores Chemosensitivity To Camptothecin (cpt)-resistant Cancer Cells, PharmSci Supplement, T2345, November 2004.

171. Helen Usansky and Patrick J. Sinko, Differentiating The Roles Of Pgp, Mrp2 And Cyp3a

In Saquinavir Rat Jejunal Permeability, PharmSci Supplement, T2216, November 2004. 172. Sung-Hack Lee, Jeevan R. Kunta, Barbara A. Perry and Patrick J. Sinko, Effect of

Ritonavir And Midazolam On the Absorption of Saquinavir In Intestinal and Vascular Access Ported Rabbits, PharmSci Supplement, W4325, November 2004.

173. Xiaoping Zhang, Yongjiu Jin, Li Wan, and Patrick Sinko, Endocytotic internalization of

R.I.-Tat-9, a cell penetrating peptide (CPP), PharmSci supplement, W4302, November 2004.

174. S. Gunaseelen, O. Debrah, L. Wan, M. Leibowitz, S. Stein, P.J. Sinko, Synthesis Of

Poly(ethylene Glycol)(peg)-based Saquinavir Prodrug Conjugates And Assessment Of Release And Anti-HIV Bioactivity Using A Novel Protease Inhibition Assay, PharmSci supplement, W4072, November 2004.

175. Pankaj V. Paranjpe, Yu Chen, Stanley Stein, Patrick. J. Sinko, Tumor-targeted

Bioconjugate Based Delivery Of Camptothecin: Design, Synthesis And In Vitro Evaluation, PharmSci supplement, W4301, November 2004.

176. Pankaj V. Paranjpe, Stanley Stein and Patrick. J. Sinko Tumor-targeted Bioconjugate

Based Delivery Of Camptothecin: Programming The Release Rates And Site Using Amino Acid And Peptide Linkers, PharmSci supplement, W4300, November 2004.

177. Piyun Chao and Patrick J. Sinko, Development And In Vitro Characterization Of A

Passive Pulmonary Targeting Camptothecin Delivery System, PharmSci supplement, W5252, November 2004.

178. R.K. Bhardwaj, D. Herrera-Ruiz, P.J. Sinko, O.S. Gudmundsson and G.T. Knipp.

Delineation of HPepT1 Mediated Uptake and Transport of Substrates Utilizing Stably Transfected HPEPT1/MDCK Clones and Caco-2 Cells. 2005 National Biotechnology Conference, San Francisco, CA, June 2005.

179. Pi-Yun Chao, Stanley Stein and Patrick J. Sinko, “Development and In Vitro

Characterization of a Novel Microsphere-Based, Passive Pulmonary Targeted Anti-Cancer Drug Delivery System Using Camptothecin As The Model Drug”, 32nd Annual Meeting


and Exposition of the Controlled Release Society, Miami Beach Florida, 251, June 2005. 180. Patrick J. Sinko, Pi-Yun Chao, Peidi Hu, and Stanley Stein, Microsphere-Based

Camptothecin Passive Lung Targeting Delivery System. Anti-Cancer Efficacy Evaluation In An Orthotopic Lung Cancer Rat Model, 32nd Annual Meeting and Exposition of the Controlled Release Society, Miami Beach Florida, 240, June 2005.

181. Helen Usansky and Patrick J. Sinko, In Vitro-In Vivo Correlation of Saquinavir Intestinal

Absorption in Male Sprague-Dawley Rats, PharmSci supplement, T2271, November 2005.

182. Helen Usansky and Patrick J. Sinko, Interplay of Pgp, Mrp2 and CYP3A in Saquinavir

Oral Pharmacokinetics in Rats, PharmSci supplement, T2272, November 2005. 183. Helen Usansky and Patrick J. Sinko, Saquinavir Absorption in Rat Jejunum Under Pgp,

Mrp2 and CYP3A Inhibition, PharmSci supplement, T2273, November 2005. 184. Piyun Chao, Peidi Hu, Stanley Stein and Patrick Sinko, Microsphere-Based Camptothecin

Passive Lung Targeting Delivery System. Anti-Cancer Efficacy Evaluation in An Orthotopic Lung Cancer Rat Model, PharmSci supplement, R6135, November 2005.

185. Hill Kutscher, Yaming Su and Patrick Sinko, Human Organic Anion-Transporting

Polypeptide OATP-C (SLC21A6) is an Uptake Transporter of Saquinavir in Microinjected Xenopus laevis Oocytes, PharmSci supplement, R6281, November 2005.

186. Sung-Hack Lee, Yaming Su and Patrick J. Sinko, In vivo Knock-down of Mouse Breast

Cancer Resistance Protein 1/Bcrp1 Mediated by Small Interfering RNA (siRNA) Transfection, PharmSci supplement, R6280, November 2005.

187. Li Wan and Patrick Sinko, Involvement Of P-Glycoprotein In The Transport Of

Saquinavir In Murine J774 Macrophages, PharmSci supplement, R6279, November 2005. 188. Xiaoping Zhang, Li Wan and Patrick Sinko, RNAi proves endocytotic internalization of

R.I.-Tat-9, a cell penetrating peptide (CPP), PharmSci supplement, T2163, November 2005.

189. Li Wan, Shahriar Pooyan, Simi Gunaseelan, Michael J. Leibowitz, Stanley Stein and

Patrick J. Sinko, Biopolymer-based Targeting Using PEG-fMLF (N-formyl-methionine-leucine-phenylalanine) Conjugates Improves Macrophage Uptake by Increasing Avidity, 33rd CRS Annual Meeting, Vienna, Austria, July 2006.

190. Patrick J. Sinko, Li Wan, Shahriar Pooyan, Simi Gunaseelan, Xiaoping Zhang, Michael J.

Leibowitz, and Stanley Stein, PEG Conjugates of R.I.CK-Tat9 and Saquinavir (SQV) Demonstrate Enhanced Intracellular Uptake and Novel Mechanisms of Synergistic Anti-HIV Activity, 33rd CRS Annual Meeting, Vienna, Austria, July 2006.

191. Sung-Hack Lee, Yaming Su, and Patrick J. Sinko, Role Of Bcrp and Mrps in an Efflux of

Zidovudine and Didanosine from Human Hek-R482 Cell Lines, PharmSci supplement, W5343, October 2006.

Patrick J. Sinko, page 50 192. H. Kutscher, Y. Singh, S. Stein, P. Sinko, Biodistribution of Silica Particles in Rats Using

Non-Invasive In vivo Imaging as a Detection Technique, PharmSci supplement, T2333, October 2006.

193. M. Palombo, L. Wan, S. Pooyan, X. Zhang, S. Stein, M. Leibowitz and P.J. Sinko,

Increasing Avidity Improves Peg-fMLF (N-Formyl-Methionine-Leucine-Phenylalanine) Nanocarrier Uptake by Macrophages, PharmSci supplement, M1123, October 2006.

194. S. Pooyan, L. Wan, P. Hu, X. Zhang, S. Stein, M. Leibowitz and P.J. Sinko, Peritoneal

Macrophage Uptake, Pharmacokinetics and Biodistribution of Macrophage-Targeted Peg-fMLF (N-Formyl-Methionyl-Leucyl-Phenylalanine) Nanocarriers, PharmSci supplement, T2327, October 2006.

195. Yaming Su, Peidi Hu, and Patrick J. Sinko, Involvement of Breast Cancer Resistant

Protein (Bcrp) in Intestinal Absorption and Disposition of Topotecan, PharmSci supplement, T2298, October 2006.

196. Xiaoping Zhang and Patrick Sinko, R.I.-Tat-9, a Cell Penetrating Peptide (CPP), Uses

Two Coexisting Pathways to Enter Cells, PharmSci supplement, T2088, October 2006. 197. S. Anumolu, Y. Singh, S. Stein and P. Sinko, Characterization of a Novel In situ Forming

Hydrogel for Sustained Ocular Drug Delivery, PharmSci supplement, R 6134, October 2006.

updated: January 31, 2007 ajg

Documents

CURRICULUM VITAE PATRICK J. SINKO, Ph.D., RPh, …sinkolab/CVFeb07.pdf · CURRICULUM VITAE PATRICK J. SINKO, Ph.D., ... Martin’s Physical Pharmacy and Pharmaceutical ... Martin’s